UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September~~March 3031, ~~2025~~2026

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-40878

IX ACQUISITION CORP.

(Exact name of registrant as specified in its charter)

Cayman Islands

98-1586922

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

~~Arch~~53 ~~12453~~ Davies ~~StreetLondon~~Street,~~United~~London W1K 5JHUnited Kingdom (Address of principal executive offices)

~~W1K 5JH~~N/A

(Zip Code)

+44 02039830450

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act: None.

Securities registered pursuant to Section 12(g) of the Act: None.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

	Large accelerated filer ☐	Accelerated filer ☐
	Non-accelerated filer ☒	Smaller reporting company ☒
		Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☒ No ☐

As of ~~December~~July 2214, ~~2025~~2026, there were 4,703,164 Class A ordinary shares, par value $0.0001 per share (the “Class A ordinary shares”), and 1,747,879 Class B ordinary shares, par value $0.0001 per share (the “Class B ordinary shares,” together with the Class A ordinary shares, the “ordinary shares”), of the registrant issued and outstanding.

Table of Contents

IX ACQUISITION CORP.

FORM 10-Q FOR THE QUARTER ENDED ~~SEPTEMBER~~MARCH 3031, ~~2025~~2026

TABLE OF CONTENTS


		Page
PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements.	1

	Condensed Consolidated Balance Sheets as of ~~September~~March 3031, ~~2025~~2026 (Unaudited) and December 31, ~~2024~~2025	1

	Unaudited Condensed Consolidated Statements of Operations for the Three ~~and Nine~~ Months Ended ~~September~~March 3031, ~~2025~~2026 and ~~2024~~2025	2

	Unaudited Condensed Consolidated Statements of Changes in Shareholders’ Deficit for the Three ~~and Nine~~ Months Ended ~~September~~March 3031, ~~2025~~2026 and ~~2024~~2025	3

	Unaudited Condensed Consolidated Statements of Cash Flows for the ~~Nine~~Three Months Ended ~~September~~March 3031, ~~2025~~2026 and ~~2024~~2025	4

	Notes to Unaudited Condensed Consolidated Financial Statements	5

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	3329

Item 3.	Quantitative and Qualitative Disclosures About Market Risk.	4539

Item 4.	Controls and Procedures.	4640

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings.	4741

Item 1A.	Risk Factors.	4741

Item 2.	Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities.	4943

Item 3.	Defaults Upon Senior Securities.	4943

Item 4.	Mine Safety Disclosures.	4943

Item 5.	Other Information.	4943

Item 6.	Exhibits.	5044

SIGNATURES

Table of Contents

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements.

IX ACQUISITION CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS


	~~September~~March 3031,		December 31,
	~~2025~~2026		~~2024~~2025
	(Unaudited)
Assets
Current assets:
Cash	$	85373,~~883~~452	$	3178,~~527~~975
Prepaid expenses		3920,~~583~~000		2725,~~052~~750
Accounts receivable, net of allowance of $2,471,333 and $500,000 as of September 30, 2025 and December 31, 2024, respectively		—		—
Accounts receivable, net of allowance of $3,453,208 and $3,125,542 as of March 31, 2026 and December 31, 2025, respectively		—		—
Due from related party		14,750		13,877
Due from AERKOMM		165,000		160,000
Total current assets		140,216		44,456
Due from related party		14,750		14,750
Total current assets		573,202		379,475
Non-current assets:
Cash held in the Trust Account		198,~~846~~926,~~616~~816		188,~~949~~781,~~539~~221
Total Assets	$	199,~~986~~500,~~832~~018	$	189,~~993~~160,~~995~~696

Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit:
Current liabilities:
Accounts payable	$	~~300~~506,~~320~~512	$	~~421~~412,~~068~~917
Accrued expenses		2,~~534~~820,~~461~~584		2,~~203~~671,~~224~~740
Working capital financing		50,000		—
Promissory note-related party		3,955,175		3,955,175
Promissory note-related party		3,955,175		3,856,641
Total current liabilities		7,282,271		7,039,832
Total current liabilities		6,839,956		6,480,933
Non-current liabilities:
Derivative warrant liabilities (1)		2,797,500		1,119,000
Derivative warrant liabilities		932,500		2,797,500
Deferred underwriting fee payable		6,050,000		6,050,000
Total non-current liabilities		86,~~847~~982,500		78,~~169~~847,~~000~~500
Total Liabilities		1514,~~687~~264,~~456~~771		1315,~~649~~887,~~933~~332

Commitments and Contingencies (Note 6)
Class A ordinary shares subject to possible redemption (1), $0.0001 par value, at approximately $12.32 and $11.77 per share, respectively; 1,610,373 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively		19,846,616		18,949,539
Class A ordinary shares subject to possible redemption, $0.0001 par value, at approximately $12.73 and $12.53 per share, respectively; 701,043 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively		8,926,816		8,781,221

Shareholders’ Deficit:
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding		—		—
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding as of March 31, 2026 and December 31, 2025		—		—
Class A ordinary shares, $0.0001 par value; 200,000,000 shares authorized (1); 4,002,121 non-redeemable shares issued or outstanding as of September 30, 2025 and December 31, 2024, respectively		401		401
Class A ordinary shares, $0.0001 par value; 200,000,000 shares authorized; 4,002,121 non-redeemable shares issued or outstanding as of March 31, 2026 and December 31, 2025		401		401
Class B ordinary shares, $0.0001 par value; 20,000,000 shares authorized; 1,747,879 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively		174		174
Class B ordinary shares, $0.0001 par value; 20,000,000 shares authorized; 1,747,879 shares issued and outstanding as of March 31, 2026 and December 31, 2025		174		174
Additional paid-in capital		—		—
Accumulated deficit		(1513,~~547~~692,~~815~~144)		(1315,~~606~~508,~~052~~432)
Total shareholders’ deficit		(1513,~~547~~691,~~240~~569)		(1315,~~605~~507,~~477~~857)
Total Liabilities, Class A Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit	$	199,~~986~~500,~~832~~018	$	189,~~993~~160,~~995~~696

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

(1) Refer to Nasdaq listing section on Note 1.

Table of Contents

IX ACQUISITION CORP.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS


	For the Three Months Ended					~~For the Nine Months Ended~~
	~~September~~March 3031,					~~September 30,~~
	~~2025~~2026		~~2024~~2025		~~ ~~	~~2025~~		~~ ~~	~~2024~~
Operating and formation (income) expenses	$	(~~177~~35,~~733~~413)	$	~~630~~281,~~844~~488		$	~~178,462~~		$	~~2,241,314~~
Income (Loss) from operations		~~177~~35,~~733~~413		(~~630~~281,~~844~~488)			~~(178,462)~~			~~(2,241,314)~~

Other income (expense):
Other income:
Income from cash held in the Trust Account		~~157~~61,~~109~~470		~~349~~150,~~967~~613			~~462,276~~			~~1,039,879~~
Interest expense on operating account		—		—			―			(68)
Change in fair value of derivative warrant liabilities		1,865,000		373,000
Benefit from credit loss		200,000		―			350,000			―
Total other income, net		1,926,470		523,613
Change in fair value of derivative warrant liabilities		(1,305,500)		—			(1,678,500)			(1,119,000)

Total other income (expense), net		(948,391)		349,967			(866,224)			(79,189)
Net income	$	1,961,883	$	242,125

Net loss	$	(770,658)	$	(280,877)		$	(1,044,686)		$	(2,320,503)
Basic and diluted weighted average shares outstanding, Class A ordinary shares subject to redemption		701,043		1,610,373

Basic and diluted net income per share, Class A ordinary shares subject to redemption	$	0.30	$	0.03
Basic and diluted weighted average shares outstanding, Class A ordinary shares		1,610,373		2,846,071			1,610,373			2,846,071
Basic and diluted weighted average shares outstanding, Class A (non-redeemable) and Class B ordinary shares		5,750,000		5,750,000
Basic and diluted net loss per share, Class A ordinary shares	$	(0.10)	$	(0.03)		$	(0.14)		$	(0.27)
Basic and diluted net income per share, Class A (non-redeemable) and Class B ordinary shares	$	0.30	$	0.03
Basic and diluted weighted average shares outstanding, Class A (non-redeemable) and Class B ordinary shares		5,750,000		5,750,000			5,750,000			5,750,000
Basic and diluted net loss per share, Class A (non-redeemable) and Class B ordinary shares	$	(0.10)	$	(0.03)		$	(0.14)		$	(0.27)

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

Table of Contents

IX ACQUISITION CORP.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT

FOR THE THREE ~~AND NINE~~ MONTHS ENDED ~~SEPTEMBER~~MARCH 3031, ~~2025~~2026


	Class A			Class B			Additional				Total
	Ordinary Shares			Ordinary Shares			Paid-in		Accumulated		Shareholders’
	Shares	Amount		Shares	Amount		Capital		Deficit		Deficit
Balance — January 1, 2025	4,002,121	$	401	1,747,879	$	174	$	—	$	(13,606,052)	$	(13,605,477)
Balance — January 1, 2026	4,002,121	$	401	1,747,879	$	174	$	—	$	(15,508,432)	$	(15,507,857)
Remeasurement of Class A ordinary shares to redemption amount	—		—	—		—		—		(~~295~~145,~~546~~595)		(~~295~~145,~~546~~595)
Net income	—		—	—		—		—		~~242~~1,~~125~~961,883		~~242~~1,~~125~~961,883
Balance — March 31, 2025	4,002,121		401	1,747,879		174		—		(13,659,473)		(13,658,898)
Balance — March 31, 2026	4,002,121	$	401	1,747,879	$	174	$	—	$	(13,692,144)	$	(13,691,569)
Remeasurement of Class A ordinary shares to redemption amount	—		—	—		—		—		(299,488)		(299,488)
Net loss	—		—	—		—		—		(516,153)		(516,153)
Balance — June 30, 2025	4,002,121		401	1,747,879		174		—		(14,475,114)		(14,474,539)
Remeasurement of Class A ordinary shares to redemption amount	—		—	—		—		—		(302,043)		(302,043)
Net loss	—		—	—		—		—		(770,658)		(770,658)
Balance — September 30, 2025	4,002,121	$	401	1,747,879	$	174	$	—	$	(15,547,815)	$	(15,547,240)

FOR THE THREE ~~AND NINE~~ MONTHS ENDED ~~SEPTEMBER~~MARCH 3031, ~~2024~~2025


	Class A			Class B			Additional				Total
	Ordinary Shares			Ordinary Shares			Paid-in		Accumulated		Shareholders’
	Shares	Amount		Shares	Amount		Capital		Deficit		Deficit
Balance — January 1, 2024	4,002,121	$	401	1,747,879	$	174	$	1,766,556	$	(11,282,258)	$	(9,515,127)
Balance — January 1, 2025	4,002,121	$	401	1,747,879	$	174	$	—	$	(13,606,052)	$	(13,605,477)
Remeasurement of Class A ordinary shares to redemption amount	—		—	—		—		~~(495,617)~~—		—(295,546)		(~~495~~295,~~617~~546)
Net loss	—		—	—		—		—		(721,742)		(721,742)
Net income	—		—	—		—		—		242,125		242,125
Balance — March 31, 2024	4,002,121		401	1,747,879		174		1,270,939		(12,004,000)		(10,732,486)
Balance — March 31, 2025	4,002,121	$	401	1,747,879	$	174	$	—	$	(13,659,473)	$	(13,658,898)
Remeasurement of Class A ordinary shares to redemption amount	—		—	—		—		(494,295)		—		(494,295)
Net loss	—		—	—		—		—		(1,317,884)		(1,317,884)
Balance — June 30, 2024	4,002,121		401	1,747,879		174		776,644		(13,321,884)		(12,544,665)
Remeasurement of Class A ordinary shares to redemption amount	—		—	—		—		(499,966)		—		(499,966)
Net loss	—		—	—		—		—		(280,877)		(280,877)
Balance — September 30, 2024	4,002,121	$	401	1,747,879	$	174	$	276,678	$	(13,602,761)	$	(13,325,508)

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

Table of Contents

IX ACQUISITION CORP.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS


	For the ~~Nine~~Three Months Ended ~~September~~March 3031,
	~~2025~~2026		~~2024~~2025

Cash Flows from Operating Activities:
Net loss	$	(1,044,686)	$	(2,320,503)
Net income	$	1,961,883	$	242,125
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Change in fair value of derivative warrant liabilities		(1,~~678~~865,~~500~~000)		1(373,~~119,~~000)
Income from cash held in the Trust Account		(~~462~~61,~~276~~470)		(1150,~~039,879~~613)
Benefit from credit loss		(350,000)		—
Changes in operating assets and liabilities:
Prepaid expenses		(13,404)		6,795
Prepaid expenses and due from related party		5,750		651
Accounts receivable		350,000		—
Due from AERKOMM		(5,000)		—
Accounts payable		~~(120~~93,~~748)~~595		~~232~~(62,~~577~~883)
Working capital financing		50,000		―
Accrued expenses		148,844		102,942
Accrued expenses		331,237		778,239
Net cash provided by (used in) operating activities		278,602		(240,778)
Net cash provided by (used in) operating activities		418,623		(1,223,771)

Cash Flows from Investing Activities:
Cash deposited in Trust Account		(~~434~~84,~~801~~125)		(~~450~~144,~~000~~933)
Net cash used in investing activities		(~~434~~84,~~801~~125)		(~~450~~144,~~000~~933)

Cash Flows from Financing Activities:
Proceeds from convertible promissory note-related party		578,534		1,658,500
Proceeds from Extension Promissory Note		—		385,934
Repayment of promissory note-related party		(480,000)		―
Net cash provided by financing activities		—		385,934
Net cash provided by financing activities		98,534		1,658,500

Net change in cash		194,477		223
Cash - beginning of the period		178,975		3,527
Cash - end of the period	$	373,452	$	3,750

Net change in cash		82,356		(15,271)
Cash - beginning of the period		3,527		24,278
Cash - end of the period	$	85,883	$	9,007

Supplemental disclosure of noncash investing and financing activities:
Remeasurement of Class A ordinary shares to redemption amount	$	~~897~~145,~~077~~595	$	1295,~~489,878~~546

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

Table of Contents

IX ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL ~~STATEMENTSSeptember~~STATEMENTSMarch 3031, ~~2025~~2026

NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS

Overview

IX Acquisition Corp. (the “Company”, “our Company,” “we” or “us”) is a blank check company incorporated in the Cayman Islands on March 1, 2021. The Company was formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (a “Business Combination”). The Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.

The Company has a wholly-owned subsidiary that was created on March 15, 2024, AKOM Merger Sub, Inc. (“Merger Sub”), a Nevada corporation and a wholly owned subsidiary of the Company ~~(“Merger Sub”)~~ and AERKOMM Inc., a Nevada corporation (“AERKOMM”). The transactions contemplated by the Merger Agreement are intended to serve as the Company’s initial Business Combination. See Note 6 for further information.

As of ~~September~~March 3031, ~~2025~~2026, the Company had not commenced any operations. All activity for the period from March 1, 2021 (inception) through ~~September~~March 3031, ~~2025~~2026 relates to the Company’s formation and the initial public offering consummated on October 12, 2021 (“Initial Public Offering”), which is described below, and since the Initial Public Offering, the search for a prospective initial Business Combination. The Company generates non-operating income in the form of interest income from the amount held in the Trust Account (as defined below), as well as late filing penalties and reimbursement of expenses from AERKOMM.

The Registration Statement on Form S-1 initially filed with the U.S. Securities and Exchange Commission (the “SEC”) on September 16, 2021 (File No. 333-259567), as amended (the “Registration Statement) for the Initial Public Offering was declared effective on October 6, 2021. On October 12, 2021, the Company consummated the Initial Public Offering of 23,000,000 Units (the “Units” and, with respect to the Class A ordinary shares included in the Units sold, the “Public Shares”, and the warrants included in the Units sold, the “Public Warrants”), including 3,000,000 Units that were issued pursuant to the underwriter’s exercise of its over-allotment option in full, at $10.00 per Unit, generating total gross proceeds of $230,000,000 (see Note 3).

Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 7,150,000 warrants (the “Private Placement Warrants”, and together with the Public Warrants, the “warrants”) at a price of $1.00 per Private Placement Warrant in a private placement to IX Acquisition Sponsor, LLC (the “Sponsor”), Cantor Fitzgerald & Co. (“Cantor”) and Odeon Capital Group, LLC (“Odeon”), generating gross proceeds of $7,150,000 (the “Private Placement”) (see Note 4).

Transaction costs amounted to $30,639,304, consisting of $4,000,000 of underwriting fees, $12,100,000 of deferred underwriting fees (See Note 6 for the difference on underwriting agreement), $13,853,689 for the excess of the fair value over the sales price of Founder Shares (as defined in Note 5) sold to the Anchor Investors (as defined in Note 5), and $685,615 of other offering costs.

Upon the closing of the Initial Public Offering on October 12, 2021, an amount of $231,150,000 from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants in the Private Placement was placed in a U.S.-based trust account (the “Trust Account”) and was initially invested only in the U.S. Department of the Treasury (the “Treasury”) obligations with maturities of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act of 1940, as amended (the “Investment Company Act”), which invest only in direct Treasury obligations. To mitigate the risk that the Company might be deemed to be an investment company for purposes of the Investment Company Act, on November 13, 2023 the Company instructed Continental Stock Transfer & Trust Company (“Continental”) to liquidate the investments held in the Trust Account, and instead to hold the funds in the Trust Account in an interest-bearing demand deposit account at a bank, with Continental continuing to act as trustee, until the earliest of: (i) the completion of the initial Business Combination; (ii) the redemption of any Public Shares properly tendered in connection with a shareholder vote to amend the amended and restated memorandum and articles of association of the Company currently in effect, as amended, (the “Amended and Restated Memorandum and Articles of Association”) to modify the substance or timing of the Company’s obligation to redeem 100% of the Public Shares if the Company does not complete the initial Business Combination within the Combination Period (as defined below); and (iii) absent an initial Business Combination within the Combination Period, the return of the funds held in the Trust Account to the Public Shareholders (as defined below) as part of the redemption of the Public Shares.

Table of Contents

IX ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~September~~March 3031, ~~2025~~2026

If the Company does not invest the proceeds as discussed above, the Company may be deemed to be subject to the Investment Company Act. If the Company is deemed to be subject to the Investment Company Act, compliance with these additional regulatory burdens would require additional expenses for which the Company has not allotted funds and may hinder the Company’s ability to complete a Business Combination. If the Company is unable to complete the initial Business Combination, the Public Shareholders may only receive their pro rata portion of the funds in the Trust Account that are available for distribution to Public Shareholders, and the warrants will expire worthless.

The Company will provide its holders of the outstanding Public Shares (the “Public Shareholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. All Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially $10.05 per Public Share, plus (x) any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations and (y) the per share portion of the Contribution (as defined below) (see Notes 5). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants. All Public Shares subject to redemption were recorded at redemption value and classified as temporary equity upon the completion of the Initial Public Offering in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480, “Distinguishing Liabilities from Equity” (“ASC 480”).

The Company will proceed with a Business Combination if a majority of the shares voted are voted in favor of the Business Combination. If a shareholder vote is not required under applicable law or stock exchange listing requirements and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association as then in effect, conduct the redemptions pursuant to the tender offer rules of the SEC, and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination. If the Company seeks shareholder approval in connection with a Business Combination, the holders of the Founder Shares prior to the Initial Public Offering (other than the Anchor Investors) (the “Initial Shareholders”), the Anchor Investors, and the Company’s executive officers and directors (“Management” or “Management Team”) agreed to vote any Founder Shares held by them, and any Public Shares purchased in or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Shareholder may elect to redeem their Public Shares irrespective of whether they (i) vote for or against the proposed transaction or (ii) were a Public Shareholder on the record date for the general meeting held to approve the proposed transaction.

Notwithstanding the above, if the Company seeks shareholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Amended and Restated Memorandum and Articles of Association provides that a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the Public Shares, without the Company’s prior written consent.

The Initial Shareholders agreed to (i) waive their redemption rights with respect to any Founder Shares and Public Shares they hold in connection with the completion of an initial Business Combination, (ii) waive their redemption rights with respect to any Founder Shares and Public Shares they hold in connection with a shareholder vote to approve an amendment to the Amended and Restated Memorandum and Articles of Association to modify the substance or timing of the Company’s obligation to redeem 100% of the Public Shares if the Company has not consummated an initial Business Combination within the Combination Period and (iii) waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares they hold if the Company fails to complete an initial Business Combination within the Combination Period. However, if the Initial Shareholders acquire Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period.

Table of Contents

IX ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~September~~March 3031, ~~2025~~2026

Combination Period and Share Redemption/Conversion Events

If the Company is unable to complete a Business Combination within a certain period of time as outlined below (“the Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account (which interest shall be net of taxes payable and up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish Public Shareholders’ rights as shareholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining shareholders and ~~Board~~the board of ~~Directors~~directors (asthe ~~defined~~“Board ~~below~~of Directors”), liquidate and dissolve, subject, in each case, to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.

The Company initially had 18 months from the closing of the Initial Public Offering (by April 12, 2023) to consummate a Business Combination as the Combination Period, prior to any amendments to the Amended and Restated Memorandum and Articles of Association to extend the duration of the Combination Period. As outlined through a series of proposals below, the Combination Period has since been extended. The Company had until January 12, 2024 to complete a Business Combination, with the right to extend the Combination Period through no later than October 12, 2024, subject to making required monthly extension deposits into the Trust Account of the lesser of (x) $50,000 or (y) $0.025 for each Class A Ordinary Share included as part of the units sold in the IPO. ~~The Company made three $50,000 monthly extension payment deposits into the Trust Account during the three-months ended June 30, 2024, extending the Combination Period to July 12, 2024.~~

~~Subsequent~~On toApril ~~June 30~~10, ~~2024~~2023, the Company ~~has~~held ~~made each of~~ the ~~applicable~~April ~~extension~~2023 ~~deposits~~Extraordinary ~~into the Trust allowing for the Business Combination Period to extend to September 12~~Meeting, ~~2024.~~at ~~On October 9~~which, ~~2024,~~ the ~~Company~~shareholders ~~held~~approved, anamong ~~extraordinary~~other ~~general~~things: ~~meeting~~(i) ~~of its shareholders. At~~ the ~~meeting, the Third~~ Extension ~~Amendment~~ Proposal; to(ii) ~~give~~ the ~~Board~~Redemption ~~the~~Limitation ~~right~~Amendment toProposal; ~~extend~~and ~~the~~(iii) ~~date by which~~ the ~~Company~~Founder ~~must~~Share ~~consummate~~Amendment aProposal. ~~Business~~Under ~~Combination~~Cayman ~~from~~Islands ~~October 12~~law, ~~2024~~the onamendments ~~a monthly basis up~~ to ~~twelve~~the ~~(12)~~Amended ~~times~~and ~~until~~Restated ~~October~~Memorandum ~~12,~~and ~~2025~~Articles ~~(or~~of ~~such~~Association ~~earlier~~took ~~date~~effect asupon ~~determined~~approval byof the ~~Board) (the “Third~~ Extension ~~Amendment”)~~Proposal, ~~was approved by depositing into~~ the ~~Company’s~~Redemption ~~trust~~Limitation ~~account~~Amendment ~~for~~Proposal ~~each~~and ~~one-month extension~~ the ~~lesser~~Founder ofShare ~~(a)~~Amendment ~~$50,000 and (b) $0~~Proposal.~~03 for each then outstanding share after giving effect to any redemptions.~~

OnIn ~~April~~connection ~~10,~~with ~~2023,~~ the ~~Company~~votes ~~held~~to anapprove ~~extraordinary general meeting of shareholders (~~the ~~“2023~~Extension ~~Extraordinary Meeting”). At the 2023 Extraordinary Meeting~~Proposal, the ~~Company’s~~Redemption ~~shareholders~~Limitation ~~approved,~~Amendment ~~among~~Proposal ~~other things, a proposal to grant the Company the right to extend the Combination Period, from April 12, 2023 to May 12, 2023 (the “Extended Date”),~~ and ~~to allow~~ the ~~Company,~~Founder ~~without~~Share ~~another~~Amendment ~~shareholder vote~~Proposal, ~~by resolution of~~ the ~~Company’s~~holders ~~board~~ of ~~directors (the “Board of Directors”)~~18, ~~to elect to further extend the Extended Date in one-month increments up to eleven additional times~~336,279 orClass aA ~~total~~ordinary ofshares upproperly toexercised ~~twelve~~their ~~months~~right ~~total, up~~ to ~~April~~redeem ~~12,~~their ~~2024~~shares ~~(the~~for ~~“Extension~~cash ~~Proposal”)~~at bya ~~amending~~redemption ~~the~~price ~~Amended and Restated Memorandum and Articles~~ of ~~Association~~approximately $10.31 ~~Under~~per ~~Cayman Islands law~~share, ~~such~~for ~~amendment~~an ofaggregate ~~the~~redemption ~~Amended~~amount ~~and Restated Memorandum and Articles~~ of ~~Association~~approximately ~~took~~$189 ~~effect upon approval of the Extension Proposal~~million. AsAfter ~~a result of~~ the ~~approval~~satisfaction of the ~~Extension Proposal~~redemptions, the ~~Company~~balance ~~was provided the ability, with monthly extension payments, but without another shareholder vote and by resolution of the Board of Directors, to extend the Extended Date~~ in ~~one-month increments through April 12, 2024, and further extending~~ the ~~Combination~~Trust ~~Period~~Account ~~up to October 12, 2024 to complete a Business Combination which~~ was ~~approved~~approximately ~~during~~$48 ~~the Extraordinary General Meeting held on December 11, 2023~~million.

AtOn ~~the~~April 13, 2023, ~~Extraordinary~~May ~~Meeting~~9, ~~the~~2023, ~~Company’s~~June ~~shareholders~~9, ~~also~~2023, ~~approved~~July to11, ~~further~~2023, ~~amend~~August ~~the~~9, ~~Amended~~2023, ~~and~~September ~~Restated~~7, ~~Memorandum~~2023, ~~and~~October ~~Articles~~12, of2023 ~~Association~~and ~~(i)~~November to13, ~~eliminate~~2023, ~~(x)~~ the ~~limitation that the~~ Company ~~may~~announced ~~not redeem Public Shares in an amount~~ that ~~would cause~~ the ~~Company’s~~Board ~~net~~of ~~tangible~~Directors ~~assets~~has elected to beextend ~~less~~the ~~than~~date ~~$5,000,001~~by ~~and~~which ~~(y)~~ the ~~limitation that the~~ Company ~~shall~~has ~~not~~to consummate a ~~Business~~business ~~Combination~~combination ~~unless~~from ~~the~~June ~~Company~~12, ~~has~~2023 ~~net~~for ~~tangible~~an ~~assets~~additional ofmonth ~~at least $5,000,001 immediately prior~~ to, orFebruary ~~upon consummation of~~12, or2024. ~~any~~In ~~greater~~connection ~~net~~with ~~tangible asset or cash requirement that may be contained in~~ the ~~agreement~~third ~~relating to~~extension, ~~such Business Combination (~~the ~~“Redemption~~Board ~~Limitation~~of ~~Amendment~~Directors ~~Proposal”)~~delivered ~~and (ii) to provide for~~ the ~~right~~Sponsor of a ~~holder~~written ofrequest ~~the Class B ordinary shares, par value $0.0001 per share,~~ to ~~convert~~draw ~~into~~down ~~Class A ordinary shares, par value~~ $~~0.0001 per share~~160,000 onunder aits ~~one~~previously-~~for-one~~disclosed ~~basis~~promissory atnote ~~any~~for ~~time and from time to time prior to~~ the ~~closing~~third ofextension. aOn ~~Business~~April ~~Combination~~26, at2023, ~~the~~May ~~election~~15, of2023, ~~the~~June ~~holder~~15, ~~(the~~2023, ~~“Founder~~July ~~Share~~13, ~~Amendment~~2023, ~~Proposal”).~~August ~~Those~~15, ~~amendments~~2023, toSeptember ~~the~~12, ~~Amended~~2023, ~~and~~October ~~Restated~~16, ~~Memorandum~~2023 and ~~Articles~~November of30, ~~Association~~2023, ~~took~~the ~~effect~~Sponsor ~~upon~~deposited ~~the~~$160,000 ~~approval~~into of the Company’s ~~shareholders.~~Trust InAccount in connection with the ~~votes~~first, ~~to approve the Extension Proposal~~second, ~~the Redemption Limitation Amendment Proposal and the Founder Share Amendment Proposal~~third, ~~the holders of 18~~fourth,~~336,279~~ ~~Class A ordinary shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $10.31 per share (the “Redemptions”)~~fifth, ~~for an aggregate redemption amount of approximately $189 million. After the satisfaction of such Redemptions~~sixth, ~~the~~seventh ~~balance~~and ineighth ~~the Trust Account was approximately $48 million~~extension.

On December 11, 2023, the Company held an extraordinary general meeting. At the meeting, the Second Extension Amendment Proposal to give the Board of Directors the right to extend the date by which the Company must consummate a Business Combination from December 12, 2023 on a monthly basis up to ten (10) times until October 12, 2024 (or such earlier date as determined by the Board of Directors) (the “Second Extension Amendment”) was approved. Under the law of the Cayman Islands, upon approval of the Second Extension Amendment Proposal by the affirmative vote of at least two-thirds (2/3) of the shareholders entitled to vote, who attended and voted at the meeting (including those who voted online), the Second Extension Amendment became effective. The Company filed the Second Extension Amendment with the Cayman Islands Registrar of Companies on December 12, 2023.

On January 19, 2024, the Company announced that the Board of Directors had elected to extend the date by which the Company has to consummate a business combination from January 12, 2024 for an additional month to February 12, 2024 and further extend March 12, 2024 and April 12, 2024. The Company’s Amended and Restated Memorandum and Articles of Association provides the Company with the right to extend the date eighteen times for an additional one month each time, from April 12, 2023, the initial date, to up to October 12, 2024. In connection with the tenth Extension, the Board of Directors delivered the Sponsor a written request to draw down $50,000 under its previously-disclosed promissory note. The Sponsor deposited $50,000 each into the Company’s Trust Account in connection with the ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth extensions on December 21, 2023, January 12, 2024, February 17, 2024, March 12, 2024, April 19, 2024, May 17, 2024, June 20, 2024, July 23, 2024, August 16, 2024, September 20, 2024, respectively, to extend the life until October 12, 2024.

Table of Contents

IX ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~September~~March 3031, ~~2025~~2026

~~Additionally,~~On ~~the~~October ~~Sponsor~~9, ~~agreed~~2024, ~~that if~~ the ~~Extension~~Company ~~Proposal~~held ~~was~~an ~~approved,~~extraordinary itgeneral ormeeting of its ~~designee~~shareholders. ~~would~~At ~~deposit~~the ~~into~~meeting, the ~~Trust~~Third ~~Account~~Extension asAmendment aProposal ~~loan, an amount equal~~ to give the ~~lesser~~Board of ~~(x)~~Directors ~~$160,000~~the orright ~~(y)~~to ~~$0.04~~extend ~~per~~the ~~Public~~date ~~Share multiplied~~ by which the ~~number~~Company ofmust ~~Public~~consummate ~~Shares~~a ~~outstanding~~Business ~~(the~~Combination ~~“Contribution”)~~from October 12, 2024 on ~~each~~a ofmonthly ~~the~~basis ~~following~~up ~~dates:~~to twelve (i12) ~~April~~times ~~13,~~until ~~2023;~~October ~~and~~12, 2025 (~~ii)~~or ~~one~~such ~~business~~earlier ~~day~~date ~~following~~as determined by the ~~public~~Board ~~announcement~~of byDirectors) (the ~~Company~~“Third ~~disclosing~~Extension ~~that~~Amendment”) was approved by depositing into the ~~Board~~Company’s ofTrust ~~Directors~~Account ~~has~~for ~~determined~~each toone-month ~~extend~~extension the ~~Extended~~lesser ~~Date~~of (a) $50,000 and (b) $0.03 for aneach ~~additional~~then ~~month~~outstanding inshare ~~accordance~~after ~~with~~giving ~~the~~effect ~~Extension~~to ~~Proposal~~any redemptions.

In connection with the ~~Contribution~~shareholders’ ~~and~~vote ~~advances~~at the ~~Sponsor~~meeting, ~~may~~1,235,698 ~~make~~shares inwere ~~the~~tendered ~~future~~for toredemption ~~the~~for ~~Company~~cash at an approximate price of $11.58 per share, for ~~working~~an ~~capital~~aggregate ~~expenses~~of approximately $14.3 million. On October 12, on2024, ~~April~~November 13, ~~2023~~2024, ~~the~~December ~~Company~~13, ~~issued~~2024, aJanuary ~~convertible~~17, ~~promissory~~2025, ~~note~~February to12, ~~the~~2025, ~~Sponsor~~March ~~with~~12, a2025, ~~principal~~May ~~amount~~13, up2025, toJune $113, ~~million~~2025, (August 8, 2025, August 13, 2025 and September 15, 2025, the ~~“Original~~Company ~~Extension~~made ~~Promissory~~twelve ~~Note”)~~deposits of $48,311 ~~which~~for ~~was~~November, ~~amended~~December, January, February, March, April, May, June, July, August, September and ~~restated~~October asextension ~~described~~contributions, ~~below~~respectively, ~~(see~~to ~~Note~~extend 5)the life until October 12, 2025.

On ~~April~~October 1310, ~~2023~~2025, the ~~Sponsor~~Company ~~advanced~~held ~~$160,000~~an ~~for~~extraordinary ~~the~~general ~~first~~meeting ~~Contribution.~~of Onits ~~May~~shareholders. 9,At ~~2023,~~ the ~~Board~~meeting, ~~of Directors elected to extend~~ the ~~Extended~~Fourth ~~Date~~Extension ~~from~~Amendment ~~May~~Proposal ~~12, 2023~~ to ~~June~~give ~~12, 2023. In connection with such election,~~ the Board of Directors ~~delivered~~ the ~~Sponsor~~right ~~a written request~~ to ~~draw~~extend ~~down $160,000 under~~ the ~~Extension~~date ~~Promissory~~by ~~Note~~which ~~(as defined below). On May 12, 2023,~~ the ~~Sponsor~~Company ~~deposited~~must ~~the~~consummate ~~$160,000~~a ~~Contribution~~Business ~~into~~Combination ~~the Trust Account in connection with this second extension of the Extended Date. On June 9, 2023, the Board of Directors elected to extend the Extended Date~~ from ~~June~~October 12, ~~2023~~2025 toon ~~July~~a ~~12,~~monthly ~~2023.~~basis Onup ~~June 12, 2023, the Sponsor deposited the $160,000 Contribution into the Trust Account in connection with this third extension. On July 11, 2023, the Board of Directors elected~~ to ~~extend~~twelve ~~the Extended Date from July~~ (12,) ~~2023~~times tountil ~~August~~October 12, ~~2023.~~2026 Onwas ~~July~~approved ~~12,~~by ~~2023,~~depositing ~~the Sponsor deposited the $160,000 Contribution~~ into the Company’s Trust Account infor ~~connection~~each ~~with~~one-month ~~this fourth~~ extension. ~~On August 9, 2023,~~ the ~~Board~~lesser of ~~Directors~~(a) ~~elected to extend the Extended Date from August 12, 2023 to September 12, 2023. On August 11, 2023, the Sponsor deposited the~~ $~~160~~40,000 ~~Contribution~~and ~~into~~(b) ~~the Trust Account in connection with this fifth extension~~$0.04 Onfor ~~September~~each ~~12,~~then ~~2023,~~outstanding ~~the~~share ~~Sponsor~~after ~~deposited~~giving ~~the~~effect ~~$160,000 Contribution into the Trust Account in connection with this nineth extension, extending the Combination Period~~ to ~~October~~any ~~12, 2023~~redemptions.

OnIn ~~May~~connection 9with the October 10, ~~2023~~2025 extraordinary general meeting, ~~pursuant~~909,330 toshares ~~the~~were ~~terms~~tendered offor ~~the~~redemption ~~Amended~~for ~~and~~cash ~~Restated~~at ~~Memorandum~~an ~~and~~approximate ~~Articles~~price of ~~Association,~~$12.35 ~~the~~per ~~Sponsor~~share, ~~the~~for ~~holder of~~ an aggregate of approximately $11.2 million. On November 4,~~002~~ 2025,~~121~~ ofNovember ~~the~~18, ~~Class~~2025, BDecember ~~ordinary~~19, ~~shares~~2025, ~~elected~~January to23, ~~convert~~2026, ~~each~~February ~~outstanding~~20, ~~Class~~2026, BMarch ~~ordinary~~23, ~~share~~2026, ~~held~~April by21, it2026, onJune a8, ~~one-for-one~~2026, ~~basis~~July ~~into~~1, ~~Class~~2026 Aand ~~ordinary~~July ~~shares~~14, ~~with~~2026, ~~immediate effect (~~the ~~“Founder~~Company ~~Conversion”).~~made ~~Following~~ten ~~the~~deposits ~~Founder~~of ~~Conversion~~$28,042 each into the Company’s ~~had~~Trust anAccount ~~aggregate~~in ofconnection 8with November 2025,~~665~~ December 2025,~~842~~ ~~Class~~January A2026, ~~ordinary~~February ~~shares~~2026, March 2026, April 2026, May 2026, June 2026, July 2026 and 1August 2026 extension contributions to extend the life until November 12,~~747~~ 2025,~~879~~ ~~Class~~December B12, ~~ordinary~~2025, ~~shares~~January ~~issued~~12, 2026, February 12, 2026, March 12, 2026, April 12, 2026, May 12, 2026, June 12, 2026, July 12, 2026 and ~~outstanding~~August 12, 2026 respectively.

OnMerger September 8, 2023, the Company issued an amended and restated promissory note in the principal amount of up to $2.5 million to the Sponsor (the “Amended and Restated Extension Promissory Note” and together with the Original Extension Promissory Note, the “Extension Promissory Note”), to amend and restate the Original Extension Promissory Note. The Amended and Restated Extension Promissory Note was issued in connection with advances the Sponsor may make, in its discretion, to the Company for working capital expenses. The Amended and Restated Extension Promissory Note bears no interest and is due and payable upon the earlier to occur of (i) the date on which the Company consummates its initial Business Combination and (ii) the date of the Company’s liquidation.Agreement

AtOn March 29, 2024, the ~~election~~Company ofentered into a Merger Agreement, by and among Merger Sub and AERKOMM (as it may be amended and/or restated from time to time, the ~~Sponsor~~“Merger Agreement”).Pursuant to the Merger Agreement, upthe Company was obligated to enter into simple agreements for future equity (the “SAFE Agreements”) with certain investors providing for investments in shares of AERKOMM’s common stock in a private placement in an aggregate amount of not less than $115,~~500~~000,000 (exercising reasonable best efforts to secure $5,000,000 within twenty (20) business days of the ~~unpaid~~date ~~principal~~of ~~balance~~the ~~under~~Merger Agreement, another $5,000,000 within forty (40) business days of the ~~Amended~~date ~~and~~of ~~Restated~~the ~~Extension~~Merger ~~Promissory~~Agreement, ~~Note~~and ~~may~~another be$5,000,000 ~~converted~~within ~~into~~sixty ~~warrants~~(60) business days of the ~~Company~~date (of the ~~“Conversion~~Merger ~~Warrants”~~Agreement) atthat ~~the~~will ~~price~~automatically convert into one share of common stock, par value $10.000001 per ~~warrant~~share, at $11.50 ~~Such~~per ~~Conversion~~share ~~Warrants~~(the ~~will~~“Company ~~have~~Common ~~terms~~Stock”) ~~identical~~and toin ~~the~~accordance ~~warrants~~with ~~issued~~such toSAFE Agreements and the ~~Sponsor~~Merger Agreement (such investments in the ~~Private~~aggregate, ~~Placement~~the “SAFE Investment”). (See Note 6 for further details).

OnNasdaq ~~October~~listing 12, 2023, the Company announced that the Board of Directors has elected to extend the Combination Period for an additional month, from October 12, 2023 to November 12, 2023. In connection with the seventh extension of the Extended Date, the Board of Directors delivered the Sponsor a written request to draw down $160,000 under the Extension Promissory Note. On October 13, 2023, the Sponsor deposited the $160,000 Contribution into the Trust Account in connection with this seventh extension.

On ~~November~~October 139, 2023, the Company ~~announced~~received ~~that~~a letter (the ~~Board~~“Total Shareholders Notice”) from the Listing Qualifications Department of ~~Directors~~the ~~has~~Nasdaq ~~elected~~Stock toMarket ~~extend~~(“Nasdaq”) notifying the ~~Combination~~Company ~~Period~~that ~~for~~it anwas ~~additional~~not ~~month,~~in ~~from~~compliance ~~November~~with 12Nasdaq Listing Rule 5450(a)(2), ~~2023~~which required the Company to ~~December~~maintain 12at least 400 total shareholders for continued listing on the Nasdaq Global Market (the “Minimum Total Holders Rule”). The Total Shareholders Notice stated that the Company had until November 24, 2023. Into ~~connection~~provide Nasdaq with a plan to regain compliance. If the ~~eighth~~plan was accepted, Nasdaq might grant an extension of ~~the~~up ~~Extended~~to ~~Date,~~180 calendar days from the ~~Board~~date of ~~Directors~~the ~~delivered~~Total Shareholders Notice to evidence compliance. If Nasdaq did not accept the ~~Sponsor~~Company’s aplan, ~~written~~the ~~request~~Company would have the opportunity to ~~draw~~appeal ~~down~~that ~~$160~~decision to a Nasdaq Hearings Panel (the “Panel”). The Total Shareholders Notice had no immediate effect on the listing of the Company’s securities,~~000~~ ~~under~~and the ~~Extension~~Company’s ~~Promissory~~securities ~~Note~~continued to trade on the Nasdaq Global Market. On November 1324, 2023, the ~~Sponsor~~Company ~~deposited~~provided its plan to Nasdaq for meeting the ~~$160~~requirements under Nasdaq Listing Rule 5450(a)(2),~~000~~ ~~Contribution~~and ~~into~~evaluated available options to regain compliance. However, there could be no assurance that the ~~Trust~~Company ~~Account~~would be able to regain compliance under Nasdaq Listing Rule 5450(a)(2), or would otherwise be in ~~connection~~compliance with ~~this~~other ~~eighth~~Nasdaq ~~extension~~listing criteria.

On December 11, 2023, the Company held an extraordinary general meeting. At the meeting, the Second Extension Amendment Proposal to give the Board the right to extend the date by which the Company must consummate a Business Combination from December 12, 2023 on a monthly basis up to ten (10) times until October 12, 2024 (or such earlier date as determined by the Board) (the “Second

Table of Contents

IX ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~September~~March 3031, ~~2025~~2026

Extension Amendment”) was approved. Under the law of the Cayman Islands, upon approval of the Second Extension Amendment Proposal by the affirmative vote of at least two-thirds (2/3) of the shareholders entitled to vote, who attended and voted at the meeting (including those who voted online), the Second Extension Amendment became effective. The Company filed the Second Extension Amendment with the Cayman Islands Registrar of Companies on December 12, 2023.

The meeting was held, in part, to satisfy the annual meeting requirement pursuant to Listing Rule 5620(a) (the “Rule”) of The Nasdaq Stock Market LLC. Pursuant to the Rule, the Company was required to hold its first annual meeting of shareholders on or prior to December 31, 2023. Because the Meeting did not technically constitute an “annual general meeting” under Cayman Islands law, the terms of the Company’s Class I directors did not expire at the meeting.

In connection with the approval of the Second Extension Amendment Proposal, the Sponsor agreed to contribute to the Company, as a loan (the “Contribution”), the lesser of (x) $50,000 or (y) $0.025 for each Class A Ordinary Share included as part of the units sold in the IPO (the “Public Shares”) that remains outstanding and was not redeemed for each calendar month (commencing on December 12, 2023 and on the 12th day of each subsequent month) until October 12, 2024, or portion thereof, that is needed to complete a Business Combination.

In connection with the vote to approve the Second Extension Amendment Proposal, the holders of 1,817,650 Public Shares properly exercised their right to redeem such shares for cash at a redemption price of approximately $11.00 per share, for an aggregate redemption amount of approximately $19.99 million. Consequently, the Contribution will be $50,000 per month needed for the Company to continue to extend the Combination Period monthly. On December 12, 2023, the Company made deposits of $50,000 for December extension contribution. The underwriters of the Initial Public Offering agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution might be less than the Initial Public Offering price per Unit ($10.00).

In order to protect the amounts held in the Trust Account, the Sponsor agreed to be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $10.05 per Public Share or (2) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account if less than $10.05 per Public Share due to reductions in the value of the trust assets, in each case net of the interest that may be withdrawn to pay the Company’s tax obligations, provided that such liability will not apply to any claims by a third-party or prospective target business that executed a waiver of any and all rights to seek access to the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.

On January 19, 2024, the Company announced that the Board had elected to extend the date by which the Company has to consummate a business combination from January 12, 2024 for an additional month to February 12, 2024 and further extend March 12, 2024 and April 12, 2024. The Company’s Amended and Restated Memorandum and Articles of Association provides the Company with the right to extend the Deadline Date eighteen times for an additional one month each time, from April 12, 2023, the initial Deadline Date, to up to October 12, 2024. In connection with the tenth Extension, the Board delivered the Sponsor a written request to draw down $50,000 under its previously-disclosed promissory note. The Sponsor deposited $50,000 each into the Company’s trust account in connection with the tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth Extensions on January 12, 2024, February 17, 2024, March 12, 2024, April 19, 2024, May 17, 2024, June 20, 2024, July 23, 2024, August 16, 2024, September 20, 2024, respectively, to extend the life until October 12, 2024.

Table of Contents

IX ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2025

On March 29, 2024, the Company entered into a Merger Agreement, by and among Merger Sub and AERKOMM (as it may be amended and/or restated from time to time, the “Merger Agreement”). Pursuant to the Merger Agreement, the Company was obligated to enter into simple agreements for future equity (the “SAFE Agreements”) with certain investors providing for investments in shares of the Company’s Common Stock in a private placement in an aggregate amount of not less than $15,000,000 (exercising reasonable best efforts to secure $5,000,000 within twenty (20) Business Days of the date of the Merger Agreement, another $5,000,000 within forty (40) Business Days of the date of the Merger Agreement, and another $5,000,000 within sixty (60) Business Days of the date of the Merger Agreement) that will automatically convert upon the closing at $11.50 per share of the Company’s Common Stock and in accordance with such SAFE Agreements and the Merger Agreement (such investments in the aggregate, the “SAFE Investment”).

On August 12, 2024, the Company and AERKOMM entered into one new SAFE Agreement (the “PIPE Minimum Investment Amount”) and amended one of the SAFE Agreements previously executed on May 13, 2024. Additionally, on July 8, 2024, the Company canceled the other SAFE Agreement that was entered into on May 13, 2024. Furthermore, on June 26, 2024, the Company and AERKOMM entered into one new SAFE Agreement. As a result, as of August 12, 2024, SAFE Agreements for an aggregate of $2,585,200 have been entered into. The SAFE Agreements will automatically convert upon the closing of the merger at $11.50 per share of the Company’s Common Stock.

On December 4, 2024, the Company and AERKOMM entered into one new SAFE Agreement. As a result, as of December 4, 2024, SAFE Agreements for an aggregate of $4,997,200 have been entered into. The SAFE Agreements will automatically convert upon the closing of the merger at $11.50 per share of the Company’s Common Stock. If the SAFE Agreements automatically convert upon the closing of the merger, in addition to 434,539 of the Company’s Common Stock, the SAFE Agreements are also convertible into an additional 94% of the number of shares of Company’s Common Stock, or 408,466 shares to be held in escrow subject to the same Milestone Events outlined in the Merger Agreement under the Incentive Merger Consideration (the “Incentive Shares”) section. (see Note 6 for disclosure related to SAFE investments section).

On June 9, 2025, the Company and AERKOMM entered into a new SAFE Agreement (the “SAFE Note Agreement No. 3”). On July 23, 2025, the Company and AERKOMM entered into a new SAFE Agreement (the “SAFE Note Agreement No. 4”). On September 5, 2025, the Company and AERKOMM entered into a new SAFE Agreement (the “SAFE Note Agreement No. 4.2”). On October 23, 2025, the Company and AERKOMM entered into another SAFE Agreement (the “SAFE Note Agreement No. 5”). As a result, as of date that this Current Report on Form 10-Q has been filed, SAFE Agreements for an aggregate of $8,997,200 have been entered into. If the SAFE Agreements automatically convert upon the closing of the merger, in addition to 782,365 of the Company’s Common Stock, the SAFE Agreements are also convertible into an additional 94% of the number of shares of Company’s Common Stock, or 735,423 shares to be held in escrow subject to the same Milestone Events outlined in the Merger Agreement under the Incentive Merger Consideration (the “Incentive Shares”) section. On June 12, 2025, AERKOMM wired $520,000 of the proceeds from SAFE Note Agreement No. 3 to fund the Company’s working capital needs from May 12, 2025 to September 12, 2025 and $150,000 of the proceeds from SAFE Note Agreement No. 3 to the Company as partial repayment of the $452,500 in payables prorated to May 12, 2005 (including $12,500 in late fees) to reimburse the working capital and general corporate expenses of the Company.

On October 9, 2024, the Company held an extraordinary general meeting of its shareholders. At the meeting, the Third Extension Amendment Proposal to give the Board the right to extend the date by which the Company must consummate a Business Combination from October 12, 2024 on a monthly basis up to twelve (12) times until October 12, 2025 (or such earlier date as determined by the Board) (the “Third Extension Amendment”) was approved by depositing into the Company’s trust account for each one-month extension the lesser of (a) $50,000 and (b) $0.03 for each then outstanding share after giving effect to any redemptions.

In connection with the shareholders’ vote at the meeting, 1,235,698 shares were tendered for redemption for cash at an approximate price of $11.58 per share, for an aggregate of approximately $14.3 million. On October 12, 2024, November 13, 2024, December 13, 2024, January 17, 2025, February 12, 2025, March 12, 2025, May 13, 2025, June 13, 2025, August 8, 2025, August 13, 2025 and September 15, 2025, the Company made twelve deposits of $48,311 for November, December, January, February, March, April, May, June, July, August, September and October extension contributions, respectively, to extend the life until October 12, 2025.

On February 12, 2025, the Company, Merger Sub and AERKOMM entered into a second amendment to the Merger Agreement (the “Amendment No. 2”) to amend and restate the definitions of both “Indebtedness” and “Working Capital”.

Table of Contents

IX ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2025

On April 12, 2025, the Company, Merger Sub and AERKOMM entered into a third amendment to the Merger Agreement (the “Amendment No. 3”) to amend and restate the closing date term.

On October 10, 2025, the Company held an extraordinary general meeting of its shareholders. At the meeting, the Fourth Extension Amendment Proposal to give the Board the right to extend the date by which the Company must consummate a Business Combination from October 12, 2025 on a monthly basis up to twelve (12) times until October 12, 2026 was approved by depositing into the Company’s trust account for each one-month extension the lesser of (a) $40,000 and (b) $0.04 for each then outstanding share after giving effect to any redemptions.

In connection with the extraordinary general meeting, 909,330 shares were tendered for redemption for cash at an approximate price of $12.34 per share, for an aggregate of approximately $11.2 million. On November 4, 2025, November 18, 2025 and December 19, 2025, the Company made three deposits of $28,042 each into the Company’s trust account in connection with November, December and January 2026 extension contributions to extend the life until November 12, 2025, December 12, 2025 and January 12, 2026, respectively.

On November 26, 2025, the Company was notified by Continental that the per-share redemption price for the October 10, 2025 redemption of public shares was underpaid by approximately $0.011 per share, resulting in an aggregate payable of $9,998 to the investors. On December 10, 2025, the Company made the payment to the investors in the aggregate amount of $9,998.

Nasdaq listing

On October 9, 2023, the Company received a letter (the “Total Shareholders Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it was not in compliance with Nasdaq Listing Rule 5450(a)(2), which required the Company to main at least 400 total holders for continued listing on the Nasdaq Global Market (the “Minimum Total Holders Rule”). The Total Shareholders Notice stated that the Company had until November 24, 2023 to provide Nasdaq with a plan to regain compliance. If the plan was accepted, Nasdaq might grant an extension of up to 180 calendar days from the date of the Total Shareholders Notice to evidence compliance. If Nasdaq did not accept the Company’s plan, the Company would have the opportunity to appeal that decision to a Nasdaq Hearings Panel (the “Panel”). The Total Shareholders Notice had no immediate effect on the listing of the Company’s securities, and the Company’s securities continued to trade on the Nasdaq Global Market. On November 24, 2023, the Company provided plan to Nasdaq for meeting the requirements under Nasdaq Listing Rule 5450(a)(2), and evaluated available options to regain compliance. However, there could be no assurance that the Company would be able to regain compliance under Nasdaq Listing Rule 5450(a)(2), or would otherwise be in compliance with other Nasdaq listing criteria.

On October 12, 2023, the Company filed a Current Report on Form 8-K with the SEC to disclose its receipt of the Total Shareholders Notice in accordance with Nasdaq Listing Rule 5810(b).

On January 18, 2024 the Company provided an update to Nasdaq of its progress on fulfilling the plan to regain compliance and received a request to provide an additional update to Nasdaq on February 20, 2024.

On February 20, 2024 the Company again updated Nasdaq on its progress in fulfilling the plan to regain compliance and continues to be proactive in regaining compliance. Pursuant to the 180-day deadline from the letter received October 9, 2023, the date for the Company to demonstrate compliance is April 6, 2024.

On April 30, 2024, the Company received a Total Shareholders Notice from Nasdaq indicating that the Company did not regain compliance with the Minimum Total Holders Rule. The Company timely requested a hearing before the Panel to appeal the Total Shareholders Notice from Nasdaq and the hearing was held on June 18, 2024. On August 5, 2024, the Panel granted the Company’s request for continued listing on the Nasdaq Global Market and confirmed that the Company was in compliance with the Minimum Total Holders Rule.

On October 7, 2024, the Company received a notice from the Nasdaq’s Listing Qualifications’ Staff stating that as the Company had not completed an initial business combination within 36 months of the effective date of its registration statement in connection with its initial public offering, it was not in compliance with Nasdaq IM 5101-2 and was therefore subject to delisting. The Company had until October 14, 2024 to request a hearing before the Panel. The Company decided to request a hearing before the Panel. Trading in the Company’s securities was suspended at the opening of business on October 14, 2024. The Company had the hearing on December 10, 2024.

Additionally, on October 7, 2024, the Company submitted its initial listing application for conducting a change of control combination for the combined company on the Nasdaq Global Market—the application used for de-SPAC (special purpose acquisition company) business combinations. On October 11, 2024, Nasdaq provided the Company with a comment letter and required documentation that the Company will need to close the initial business combination.

On December 10, 2024, the Company received a notice from the Nasdaq Listing Qualifications Hearings acknowledging that the Company had withdrawn its appeal of the October 7, 2024 delisting determination issued by the Nasdaq Listings Qualifications Staff. Accordingly, trading in the Company’s securities was suspended at the open of trading on December 12, 2024. On June 6, 2025, the Company filed a Form 25 Notification of Delisting with the SEC which removed the Company’s securities from on the Nasdaq Stock Market. The Company’s Common Stock, Units and Warrants began to be quoted on the Pink Markets operated on The OTC Market systems (“OTC Market”) under the symbols “IXQUF”, “IXAQF” and “IXQWF.”

Table of Contents

IX ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~September~~March 3031, ~~2025~~2026

On December 10, 2024, the Company received a notice from the Nasdaq Listing Qualifications Hearings acknowledging that the Company had withdrawn its appeal of the October 7, 2024 delist determination issued by the Nasdaq Listings Qualifications Staff. Accordingly, trading in the Company’s securities was suspended at the open of trading on December 12, 2024. On June 6, 2025, the Company filed a Form 25 Notification of Delisting with the SEC which removed the Company’s securities from on the Nasdaq Stock Market. The Company’s Common Stock and Warrants began to be quoted its on the Pink Markets operated on The OTC Market systems (“OTC Market”) under the symbols “IXAQF” and “ IXQWF.”

Resignation of Directors and Certain Officers

On September 23, 2024, Karen Bach resigned as the Company’s Chief Executive Officer, Andrew Bartley resigned as the Company’s independent director, chair of audit committee and member of compensation committee and Teresa Barger resigned as the Company’s independent director and member of both the audit committee and the compensation committee. On October 9, 2024, upon the submission of Karen Bach’s resignation as the Chief Executive Officer, the Board appointed Noah Aptekar, the Company’s Chief Financial Officer, Chief Operations Officer and director, as the Company’s Chief Executive Officer, effective upon the effectiveness of resignation of Karen Bach. The Company’s board appointed Eduardo Marini, an independent director, as the Company’s chair of audit committee and member of compensation committee.

NOTE 2. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GOING CONCERN

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and Article 10 of Regulation S-X.

Accordingly, certain disclosures included in the annual financial statements have been condensed or omitted from these unaudited condensed consolidated financial statements as they are not required for interim unaudited condensed consolidated financial statements under GAAP and the rules of the SEC. In the opinion of management, all adjustments (consisting of normal accruals) considered for a fair presentation have been included. ~~Operating results for the three and nine months ended September 30, 2025 are not necessarily indicative of the results that may be expected for the year ending December 31, 2025 or any future period.~~

The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, ~~2024~~2025, as filed with the SEC on April 39, ~~2025~~2026 (the “~~2024~~2025 Annual Report”), which contains the audited financial statements and notes thereto. The ~~financial~~interim ~~information~~results asfor ofthe ~~September~~three ~~30,~~months ~~2025~~ended March 31, 2026 is ~~derived~~not ~~from~~necessarily indicative of the ~~audited~~results ~~financial~~to ~~statements~~be ~~presented~~expected infor the ~~2024~~year ~~Annual~~ending ~~Report~~December 31, 2026 or for any future periods.

Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, which was formed on March 15, 2024. All significant intercompany balances and transactions have been eliminated in consolidation.

Going Concern Consideration

As of ~~September~~March 3031, ~~2025~~2026, the Company had approximately $85373,~~883~~000 in cash held outside of the Trust Account and a working capital deficit of approximately $6.7 million. The Company has incurred and expects to continue to incur significant costs in pursuit of its acquisition plans. In connection with the Company’s assessment of going concern considerations in accordance with FASB ASC Topic 205-40, “Presentation of Financial Statements - Going Concern” (“ASC 205-40”), the Company has until October 12, 2026, if all extensions of the Extended Date are exercised, to consummate a Business Combination. It is uncertain that the Company will be able to consummate a Business Combination by this time, and if a Business Combination is not consummated by this date, then there will be a mandatory liquidation and subsequent dissolution of the Company.

12Management has determined that the liquidity condition and mandatory liquidation, should a Business Combination not occur, and potential subsequent dissolution of the Company raises substantial doubt about its ability to continue as a going concern for a period of time within one year after the date that the accompanying unaudited condensed consolidated financial statements are issued.

~~Table~~Management plans to address this uncertainty through the initial Business Combination as discussed above. There is no assurance that the Company’s plans to consummate the initial Business Combination will be successful or successful within the Combination Period. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of ~~Contents~~this uncertainty.

IX ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2025

consummate a Business Combination by this time, and if a Business Combination is not consummated by this date, then there will be a mandatory liquidation and subsequent dissolution of the Company.

Management has determined that the liquidity condition and mandatory liquidation, should a Business Combination not occur, and potential subsequent dissolution of the Company raises substantial doubt about its ability to continue as a going concern for a period of time within one year after the date that the accompanying condensed consolidated financial statements are issued.

Management plans to address this uncertainty through the initial Business Combination as discussed above. There is no assurance that the Company’s plans to consummate the initial Business Combination will be successful or successful within the Combination Period. The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the accompanying condensed consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period, difficult or impossible because of the potential differences in accounting standards used.10

Use of Estimates

The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires Management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the accompanying condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates are related to the fair value of the warrants.

Making estimates requires Management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which Management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. As of September 30, 2025 and 2024, the Company has not experienced losses on these accounts.

Table of Contents

IX ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~September~~March 3031, ~~2025~~2026

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the accompanying unaudited condensed consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period, difficult or impossible because of the potential differences in accounting standards used.

Use of Estimates

The preparation of the accompanying unaudited condensed consolidated financial statements in conformity with GAAP requires Management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the accompanying unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates are related to the fair value of the warrants.

Making estimates requires Management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed consolidated financial statements, which Management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. As of March 31, 2026 and December 31, 2025, the Company has not experienced losses on these accounts.

Cash and Cash Equivalents

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of ~~September~~March 3031, ~~2025~~2026 and December 31, ~~2024~~2025.

Cash Held in the Trust Account

The Company’s portfolio of investments was initially comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account were comprised of U.S. government securities, the investments were classified as “trading securities”. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments are recognized at “fair value”. Trading securities and investments in money market funds are presented on the accompanying condensed consolidated balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in income from investments held in the Trust Account in the accompanying unaudited condensed consolidated statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.

To mitigate the risk that the Company might be deemed to be an investment company for purposes of the Investment Company Act, on November 13, 2023 the Company instructed Continental to liquidate the investments held in the Trust Account and instead to hold the funds in the Trust Account in an interest-bearing demand deposit account at a bank, with Continental continuing to act as trustee, until the earlier of: (i) the consummation of a Business Combination or (ii) the distribution of the Trust Account to the Company’s shareholders (see Note 1). As of ~~September~~March 3031, ~~2025~~2026 and December 31, ~~2024~~2025, the assets held in the Trust Account were in cash.

~~Derivative Financial Instruments~~11

The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with FASB ASC Topic 815, “Derivatives and Hedging” (“ASC 815”). Derivative instruments are initially recorded at fair value on the grant date and re-valued at each reporting date, with changes in the fair value reported in the accompanying consolidated statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative warrant liabilities are classified as non-current liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. The Company evaluated the Public Warrants and Private Placement Warrants in accordance with ASC 480 and ASC 815 and concluded that a provision in the warrant agreement related to certain tender or exchange offers precludes the Public Warrants and Private Placement Warrants from being accounted for as components of equity. As the Public Warrants and Private Placement Warrants meet the definition of a derivative as contemplated in ASC 815, they were recorded as derivative liabilities on the accompanying condensed consolidated balance sheets and measured at fair value at inception (on the date of the Initial Public Offering) and at each reporting date in accordance with FASB ASC Topic 820, “Fair Value Measurement” (“ASC 820”), with changes in fair value recognized in the accompanying consolidated statements of operations in the period of change. The determination of fair value for the warrant liabilities represents a significant estimate within the accompanying condensed consolidated financial statements.

Convertible Instruments

The Company accounts for that feature conversion options in its promissory notes in accordance with ASC 815. ASC 815 requires companies to bifurcate conversion options from their host instruments and account for them as freestanding derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) a promissory note that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

Table of Contents

IX ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~September~~March 3031, ~~2025~~2026

Derivative Financial Instruments

The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with FASB ASC Topic 815, “Derivatives and Hedging” (“ASC 815”). Derivative instruments are initially recorded at fair value on the grant date and re-valued at each reporting date, with changes in the fair value reported in the accompanying unaudited condensed consolidated statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative warrant liabilities are classified as non-current liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. The Company evaluated the Public Warrants and Private Placement Warrants in accordance with ASC 480 and ASC 815 and concluded that a provision in the warrant agreement related to certain tender or exchange offers precludes the Public Warrants and Private Placement Warrants from being accounted for as components of equity. As the Public Warrants and Private Placement Warrants meet the definition of a derivative as contemplated in ASC 815, they were recorded as derivative liabilities on the accompanying condensed consolidated balance sheets and measured at fair value at inception (on the date of the Initial Public Offering) and at each reporting date in accordance with FASB ASC Topic 820, “Fair Value Measurement” (“ASC 820”), with changes in fair value recognized in the accompanying unaudited condensed consolidated statements of operations in the period of change. The determination of fair value for the warrant liabilities represents a significant estimate within the accompanying unaudited condensed consolidated financial statements.

Convertible Instruments

The Company accounts for conversion options in its promissory notes in accordance with ASC 815. ASC 815 requires companies to bifurcate conversion options from their host instruments and account for them as freestanding derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) a promissory note that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

Fair Value of Financial Instruments

“Fair value” is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. ASC 820 establishes a fair value hierarchy that prioritizes and ranks the level of observability of inputs used to measure investments at fair value. The observability of inputs is impacted by a number of factors, including the type of investment, characteristics specific to the investment, market conditions and other factors. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Investments with readily available quoted prices or for which fair value can be measured from quoted prices in active markets will typically have a higher degree of input observability and a lesser degree of judgment applied in determining fair value.

The carrying amounts reflected in the accompanying condensed consolidated balance sheets for cash, due from related party, and accounts payable approximate fair value due to their short-term nature. The three levels of the fair value hierarchy under ASC 820 are as follows:

●

“Level 1”, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;

●

“Level 2”, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

●

“Level 3”, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

Table of Contents

IX ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2026

In some cases, the inputs used to measure fair value might fall within different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the investment is categorized in its entirety is determined based on the lowest level input that is significant to the investment. Assessing the significance of a particular input to the valuation of an investment in its entirety requires judgment and considers factors specific to the investment. The categorization of an investment within the hierarchy is based upon the pricing transparency of the investment and does not necessarily correspond to the perceived risk of that investment.

See Note 9 for additional information on assets and liabilities measured at fair value.

Class A Ordinary Shares Subject to Possible Redemption

All of the 23,000,000 Class A ordinary shares sold as part of the Units in the Initial Public Offering and subsequent full exercise of the underwriters’ over-allotment option contain a redemption feature that allows for the redemption of such Public Shares (i) in connection with the Company’s liquidation, (ii) if there is a shareholder vote or tender offer in connection with the Business Combination and (iii) in connection with certain amendments to the Amended and Restated Memorandum and Articles of Association. In accordance with SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480, redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity. Therefore, all Public Shares have been classified outside of permanent equity.

The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares are affected by charges against additional paid in capital and accumulated deficit.

15As of March 31, 2026 and December 31, 2025, the Class A ordinary shares subject to redemption reflected in the accompanying condensed consolidated balance sheets are reconciled in the following table:

Table of Contents

IX ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2025

As of September 30, 2025 and December 31, 2024, the Class A ordinary shares subject to redemption reflected in the accompanying condensed consolidated balance sheets are reconciled in the following table:


Class A ordinary shares subject to possible redemption — December 31, 2024		18,949,539
	Shares		Amount
Plus:
Class A ordinary shares subject to possible redemption — December 31, 2025	701,043		$	8,781,221
Increase in redemption value of Class A ordinary shares subject to redemption		295,546
Plus:
Class A ordinary shares subject to possible redemption — March 31, 2025	$	19,245,085
Increase in redemption value of Class A ordinary shares subject to redemption	—			145,595
Plus:
Class A ordinary shares subject to possible redemption — March 31, 2026	701,043		$	8,926,816
Increase in redemption value of Class A ordinary shares subject to redemption		299,488
Class A ordinary shares subject to possible redemption — June 30, 2025		19,544,573
Plus:
Increase in redemption value of Class A ordinary shares subject to redemption		302,043
Class A ordinary shares subject to possible redemption — September 30, 2025	$	19,846,616

Offering Costs associated with the Initial Public Offering

Offering costs consisted of legal, accounting, underwriting fees and other costs incurred through the Initial Public Offering that were directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with derivative warrant liabilities were expensed as incurred and presented as non-operating expenses in the accompanying unaudited condensed consolidated statements of operations. Offering costs associated with the Class A ordinary shares were charged against the carrying value of Class A ordinary shares subject to possible redemption upon the completion of the Initial Public Offering. Deferred underwriting commissions are classified as non-current liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.

Income Taxes

The Company accounts for income taxes under FASB ASC Topic 740, “Income Taxes” (“ASC 740”). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the unaudited condensed consolidated financial statements and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.

ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s unaudited condensed consolidated financial statements and prescribes a recognition threshold and measurement process for unaudited condensed consolidated financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transitions. Based on the Company’s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the accompanying condensed consolidated financial statements.

The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of September 30, 2025 and December 31, 2024. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. There are no taxes in the Cayman Islands and accordingly income taxes are not levied on the Company. Consequently, income taxes are not reflected in the accompanying condensed consolidated financial statements.13

On July 4, 2025, President Trump signed into law the One Big Beautiful Bill Act (“OBBA”). ASC 740, “Income Taxes”, requires the effects of changes in tax laws to be recognized in the period in which the legislation is enacted. The Company is currently evaluating the impact of the new law. However, none of the tax provisions are expected to have a significant impact on the Company’s financial statements.

Table of Contents

IX ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~September~~March 3031, ~~2025~~2026

~~Net~~recognized, ~~Loss~~a ~~Per~~tax ~~Ordinary~~position ~~Share~~must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transitions. Based on the Company’s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the accompanying unaudited condensed consolidated financial statements.

The Company ~~complies~~recognizes ~~with~~accrued ~~accounting~~interest and ~~disclosure~~penalties ~~requirements~~related ofto ~~FASB~~unrecognized ~~ASC~~tax ~~Topic~~benefits ~~260~~as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of March 31, ~~“Earnings~~2026 ~~Per~~and ~~Share”~~December ~~(“ASC~~31, ~~260”)~~2025. The Company ~~has~~is ~~two~~currently ~~classes~~not aware of ~~shares~~any issues under review that could result in significant payments, ~~the~~accruals ~~Class~~or Amaterial ~~ordinary~~deviation ~~shares~~from its position. There are no taxes in the Cayman Islands and ~~Class~~accordingly Bincome ~~ordinary~~taxes ~~shares~~are not levied on the Company. ~~Loss~~Consequently, isincome ~~shared~~taxes ~~pro~~are ~~rata~~not ~~between~~reflected in the ~~two~~accompanying ~~classes~~unaudited ofcondensed ~~shares~~consolidated financial statements.

~~Net~~On ~~loss~~July ~~per~~4, ~~ordinary~~2025, ~~share~~President isTrump ~~computed~~signed byinto ~~dividing~~law ~~net loss by~~ the ~~weighted-average~~One ~~number~~Big ofBeautiful ~~ordinary~~Bill ~~shares~~Act ~~outstanding~~(“OBBBA”). ~~during~~ASC ~~the~~740, ~~period.~~“Income ~~Remeasurement~~Taxes”, ~~associated~~requires ~~with~~ the ~~redeemable~~effects ~~Class~~of Achanges ~~ordinary~~in ~~shares~~tax islaws ~~excluded~~to ~~from~~be ~~net~~recognized ~~loss~~in ~~per share as~~ the ~~redemption~~period ~~value~~in ~~approximates~~which ~~fair value. Therefore,~~ the ~~loss~~legislation ~~per~~is ~~share calculation allocates loss shared pro rata between redeemable and non-redeemable ordinary shares~~enacted. The Company has ~~not~~analyzed ~~considered~~and ~~the~~accounted ~~effect~~for of the ~~exercise~~impacts of ~~the~~OBBBA ~~Public Warrants~~ and ~~Private~~determined ~~Placement~~there ~~Warrants~~is tono ~~purchase~~material animpact ~~aggregate~~on ~~of 18,650,000 shares in~~ the ~~calculation~~Company’s ofunaudited ~~diluted~~condensed ~~loss~~consolidated ~~per~~financial ~~share, since the exercise of the warrants is contingent upon the occurrence of future events~~statements.

~~The~~Net ~~following~~Income ~~tables~~Per ~~reflect~~Ordinary ~~the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts):~~Share

The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share” (“ASC 260”). The Company has two classes of shares, the Class A ordinary shares and Class B ordinary shares. Income is shared pro rata between the two classes of shares.

Net income per ordinary share is computed by dividing net income by the weighted-average number of ordinary shares outstanding during the period. Remeasurement associated with the redeemable Class A ordinary shares is excluded from net income per share as the redemption value approximates fair value. Therefore, the income per share calculation allocates income shared pro rata between redeemable and non-redeemable ordinary shares. The Company has not considered the effect of the exercise of the Public Warrants and Private Placement Warrants to purchase an aggregate of 18,650,000 shares in the calculation of diluted income per share, since the exercise of the warrants is contingent upon the occurrence of future events.

The following tables reflect the calculation of basic and diluted net income per ordinary share (in dollars, except per share amounts):


	For the Three Months					~~For the Nine Months~~
	Ended ~~September~~March 3031,					~~Ended September 30,~~
	~~2025~~2026		~~2024~~2025		~~ ~~	~~2025~~		~~ ~~	~~2024~~
Class A Ordinary Shares subject to possible redemption
Numerator: Net loss allocable to Class A ordinary shares (Redeemable)	$	(168,612)	$	(92,995)		$	(228,566)		$	(768,294)
Numerator: Net income allocable to Class A ordinary shares (Redeemable)	$	213,200	$	52,974
Denominator: Weighted Average Class A ordinary shares (Redeemable)
Basic and diluted weighted average shares outstanding		1701,~~610,373~~043		21,~~846~~610,~~071~~373			~~1,610,373~~			~~2,846,071~~
Basic and diluted net loss per share	$	(0.10)	$	(0.03)		$	(0.14)		$	(0.27)
Basic and diluted net income per share	$	0.30	$	0.03

Class A (non-redeemable) and Class B Ordinary Shares
Numerator: Net loss allocable to Class A ordinary shares (non-redeemable) and Class B ordinary shares		(602,046)		(187,881)			(816,120)			(1,552,208)
Numerator: Net income allocable to Class A ordinary shares (non-redeemable) and Class B ordinary shares	$	1,748,683	$	189,151
Denominator:
Weighted Average Class A (non-redeemable) and Class B ordinary shares — Basic and diluted weighted average shares outstanding		5,750,000		5,750,000			~~5,750,000~~			~~5,750,000~~
Basic and diluted net loss per share	$	(0.10)	$	(0.03)		$	(0.14)		$	(0.27)
Basic and diluted net income per share	$	0.30	$	0.03

~~Recent Accounting Pronouncements~~14

Adopted in fiscal year 2024

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in this ASU require disclosures, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief operating officer decision maker (“CODM”), as well as the aggregate amount of other segment items included in the reported measure of segment profit or loss. The ASU requires that a public entity disclose the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. Public entities will be required to provide all annual disclosures currently required by Topic 280 in interim periods, and entities with a single reportable segment are required to provide all the disclosures required by the amendments in this ASU and existing segment disclosures in Topic 280. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. At December 31, 2024, the Company adopted the standard, retrospectively. The adoption of ASU 2023-07 had no material impact on the Company’s condensed consolidated financial statements (see Note 10 for details).

To be adopted in future periods

Table of Contents

IX ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~September~~March 3031, ~~2025~~2026

~~Early~~Recent ~~adoption~~Accounting ~~is permitted. The Company’s management does not believe the adoption of ASU 2023-09 will have a material impact on its condensed consolidated financial statements and disclosures.~~Pronouncements

In November 2024, the FASB issued Accounting Standards Update (“ASU”) Topic 2024-03, “Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses” (“ASU 2024-03”), requiring public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03.

Management does not believe there are any material recently issued, but not yet effective, accounting standards that, if currently adopted, would have a material effect on the accompanying unaudited condensed consolidated financial statements.

NOTE 3. INITIAL PUBLIC OFFERING

Pursuant to the Initial Public Offering, which was consummated on October 12, 2021, the Company sold 23,000,000 Units, including 3,000,000 Units that were issued pursuant to the underwriters’ exercise of their over-allotment option in full, at a purchase price of $10.00 per Unit. Each Unit consists of one Public Share and one-half of one Public Warrant. Each Public Warrant entitles the holder to purchase one Class A ordinary share at an exercise price of $11.50 per whole share (see Note 7).

NOTE 4. PRIVATE PLACEMENT

Simultaneously with the closing of the Initial Public Offering, the Sponsor, Cantor and Odeon purchased an aggregate of 7,150,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant ($7,150,000 in the aggregate), $19,982 of which was not funded by the Sponsor at the time of the Private Placement and recorded as a subscription receivable as of December 31, 2021. The subscription receivable was paid on April 12, 2022.

Each Private Placement Warrant is exercisable to purchase one Class A ordinary share at a price of $11.50 per share. The proceeds from the Private Placement were added to the net proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the Private Placement will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless.

NOTE 5. RELATED PARTY TRANSACTIONS

Founder Shares

On March 11, 2021, the Sponsor was issued 5,750,000 Class B ordinary shares (the “Founder Shares”) for an aggregate of $25,000 paid to cover certain expenses on behalf of the Company. The Founder Shares included an aggregate of up to 750,000 Class B ordinary shares subject to forfeiture by the Sponsor to the extent that the underwriters’ over-allotment option was not exercised in full or in part, so that the Sponsor and its permitted transferees would own, on an as-converted basis, 20% of the Company’s issued and outstanding shares after the Initial Public Offering. The underwriters exercised the over-allotment in full simultaneously with the closing of the Initial Public Offering, thus the 750,000 Class B ordinary shares are no longer subject to forfeiture.

On May 9, 2023, pursuant to the terms of the Amended and Restated Memorandum and Articles of Association, the Sponsor elected to convert all 4,002,121 Founder Shares it held on a one-for-one basis into Class A ordinary shares, with immediate effect. Following this Founder Conversion and the Redemptions, the Company had an aggregate of 8,665,842 Class A ordinary shares and 1,747,879 Class B ordinary shares issued and outstanding.

1815

Table of Contents

IX ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~September~~March 3031, ~~2025~~2026

The Initial Shareholders agreed that, subject to certain limited exceptions, the Founder Shares will not be transferred, assigned, or sold until the earlier of (i) one year after the completion of a Business Combination or (ii) subsequent to an initial Business Combination, (x) if the closing price of Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after an initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, share exchange or other similar transaction that results in all of the Public Shareholders having the right to exchange their ordinary shares for cash, securities or other property.

A total of (i) eight investors (the “Anchor Investors”), purchased 1,980,000 Units in the Initial Public Offering at the offering price of $10.00 per Unit: (ii) six Anchor Investors purchased 980,000 Units in the Initial Public Offering at the offering price of $10.00 per Unit; (iii) one Anchor Investor purchased 780,000 Units in the Initial Public Offering at the offering price of $10.00 per Unit; and (iv) one Anchor Investor purchased 500,000 Units in the Initial Public Offering at the offering price of $10.00 per Unit. Pursuant to such Units, the Anchor Investors have not been granted any shareholder or other rights in addition to those afforded to the Company’s other Public Shareholders. Further, the Anchor Investors are not required to (x) hold any Units, Class A ordinary shares or warrants they may purchase in the Initial Public Offering or thereafter for any amount of time, (y) vote any Class A ordinary shares they may own at the applicable time in favor of the Business Combination or (z) refrain from exercising their right to redeem their Public Shares at the time of the Business Combination. The Anchor Investors have the same rights to the funds held in the Trust Account with respect to the Class A ordinary shares underlying the Units purchased in the Initial Public Offering as the rights afforded to the Company’s other Public Shareholders.

Each Anchor Investor entered into separate investment agreements (the “Anchor Investment Agreements”) with the Company and the Sponsor pursuant to which each Anchor Investor purchased a specified number of Founder Shares, or an aggregate of 1,747,879 Founder Shares, from the Sponsor for $0.004 per share, or an aggregate purchase price of $6,992 at the closing of the Initial Public Offering. Pursuant to the investment agreements, the Anchor Investors agreed to (a) vote any Founder Shares held by them in favor of the Business Combination and (b) subject any Founder Shares held by them to the same lock-up restrictions as the Founder Shares held by the Sponsor and independent directors.

The Company estimated the fair value of the Founder Shares attributable to the Anchor Investors to be $13,860,681 or $7.93 per share recognized upon the Initial Public Offering. The Company determined the fair value based on a stock price simulation performed by a third party. The excess of the fair value of the Founder Shares sold over the purchase price of $6,992 (or $0.004 per share) was determined to be an offering cost in accordance with Staff Accounting Bulletin Topic 5A, “Expenses of Offering”. Accordingly, the offering cost was allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to derivative warrant liabilities were expensed in the accompanying unaudited condensed consolidated statements of operations. Offering costs allocated to the Public Shares were charged to temporary equity upon the completion of the Initial Public Offering.

Prior to the First Extension vote in April 12, 2023, the owners of all of the Founders Shares distributed pursuant to the Anchor Investment Agreements all entered into a first amendment of such agreement, such that the transferred shares shall, in the same proportion applicable to the Founder Shares held by the Sponsor, be automatically, and without further action of any of the parties, subject to any cut-back, reduction, mandatory repurchase, redemption, forfeiture, vesting or revesting, earnouts or other concessions agreed upon by the Company and the Sponsor in connection with the Company’s entry into an agreement with respect to, or the consummation of, an initial business combination.

Administrative Support Agreement

On October 6, 2021, the Company entered into an agreement with the Sponsor, to pay up to $10,000 per month for office space, secretarial and administrative services. Upon completion of a Business Combination or the Company’s liquidation, the Company will cease paying these monthly fees; however, the Sponsor waived these fees for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2025~~2026 and ~~2024~~2025.

19Related Party Loans

Table of Contents

IX ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~September~~March 3031, ~~2025~~2026

~~Related~~Private ~~Party~~Placement Warrants, each exercisable to purchase one Class A ordinary share at $11.50 per share, at a price of $1.00 per warrant, or up to $1,400,000 in the aggregate. In addition, in order to finance transaction costs in connection with an intended initial Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the Company’s officers and directors may, but are not obligated to (except in the case of the Committed Sponsor Loans), loan the Company additional funds as may be required on a non-interest basis (together with the Committed Sponsor Loans, the “Working Capital Loans”). If the Company completes an initial Business Combination, the Company would repay any such Working Capital Loans. In the event that the initial Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay any such Working Capital Loans but no proceeds from the Trust Account would be used for such repayment. Up to $1,400,000 of such loans (which amount includes the Committed Sponsor Loans) may be convertible into warrants of the post Business Combination entity at a price of $1.00 per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants. As of March 31, 2026 and December 31, 2025, there were no borrowings under any Working Capital Loans.

The Sponsor has committed to loan the Company an aggregate of up to $1,400,000 for working capital purposes (“Committed Sponsor Loans”), at the Company’s request, on or after January 15, 2022. Such Committed Sponsor Loans will be convertible into Private Placement Warrants, each exercisable to purchase one Class A ordinary share at $11.50 per share, at a price of $1.00 per warrant, or up to $1,400,000 in the aggregate. In addition, in order to finance transaction costs in connection with an intended initial Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the Company’s officers and directors may, but are not obligated to (except in the case of the Committed Sponsor Loans), loan the Company additional funds as may be required on a non-interest basis (together with the Committed Sponsor Loans, the “Working Capital Loans”). If the Company completes an initial Business Combination, the Company would repay any such Working Capital Loans. In the event that the initial Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay any such Working Capital Loans but no proceeds from the Trust Account would be used for such repayment. Up to $1,400,000 of such loans (which amount includes the Committed Sponsor Loans) may be convertible into warrants of the post Business Combination entity at a price of $1.00 per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants. As of September 30, 2025 and December 31, 2024, there were no borrowings under any Working Capital Loans.

In connection with the Contribution and advances the Sponsor may make in the future to the Company for working capital expenses, on April 13, 2023, the Company issued the Extension Promissory Note to the Sponsor with a principal amount up to $1 million. The Extension Promissory Note bears no interest and is repayable in full upon the earlier of (a) the date of the consummation of the Business Combination, or (b) the date of the Company’s liquidation. If the Company does not consummate an initial Business Combination within the Combination Period, the Extension Promissory Note will be repaid only from funds held outside of the Trust Account or will be forfeited, eliminated or otherwise forgiven. Upon maturity, the outstanding principal of the Extension Promissory Note may be converted into warrants, at a price of $1.00 per warrant, at the option of the Sponsor. Such warrants will have terms identical to the warrants issued to the Sponsor in the Private Placement. The Contribution and any drawdowns in connection with the Extension Promissory Note are subject to unanimous written consent of the Board of Directors and the consent of the Sponsor.

On September 8, 2023, the Company issued the Amended and Restated Extension Promissory Note in the principal amount of up to $2.5 million to the Sponsor, to amend and restate the Extension Promissory Note. The Amended and Restated Extension Promissory Note was issued in connection with advances the Sponsor may make, in its discretion, to the Company for working capital expenses. The Amended and Restated Extension Promissory Note bears no interest and is due and payable upon the earlier to occur of (i) the date on which the Company consummates its initial Business Combination and (ii) the date of the Company’s liquidation.

On April 18, 2024, the Company amended and restated the convertible promissory note, dated as of September 8, 2023, previously issued to Sponsor, to increase the aggregate principal amount to up to $3,500,000 (as amended and restated, the “Note”). The Note was issued in connection with advances the Sponsor may make, in its discretion, to the Company for working capital expenses. The Note bears no interest and is due and payable upon the earlier to occur of (i) the date on which the Company consummates its initial business combination and (ii) the date of the liquidation of the Company.

On September 20, 2024, the Company amended and restated the convertible promissory note, dated as of September 8, 2023, previously issued to Sponsor, to increase the aggregate principal amount to up to $4,500,000 (as amended and restated, the “Note”). The Note was issued in connection with advances the Sponsor may make, in its discretion, to the Company for working capital expenses. The Note bears no interest and is due and payable upon the earlier to occur of (i) the date on which the Company consummates its initial business combination and (ii) the date of the liquidation of the Company.

At the election of the Sponsor, up to $1,500,000 of the unpaid principal balance under the Amended and Restated Extension Promissory Note may be converted into Conversion Warrants at the price of $1.00 per warrant. Such Conversion Warrants will have terms identical to the warrants issued to the Sponsor in the Private Placement.

On August 18, 2025 and September 10, 2025, the Company repaid an aggregate of $480,000 under the Extension Promissory Note. As of ~~September~~March 3031, ~~2025,~~2026 ~~the~~and ~~Company had a total of $3,955,175 drawn on the Extension Promissory Note. As of~~ December 31, ~~2024~~2025, the Company had a total of $3,~~856~~955,~~641~~175 drawn on the Extension Promissory Note. In accordance with ASC 815 the Company analyzed the fair value of the derivative included in the conversion options and determined its value at zero since inception of each advance under the note, see Note 9 for further information.

20Due from related party

The Company covered certain expenses on behalf of its Sponsor, paying $14,750 as of March 31, 2026 and December 31, 2025, of which such amount is included in due from related party in the accompanying condensed consolidated balance sheets.

Table of Contents

IX ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~September~~March 3031, ~~2025~~2026

Due from related party

The Company covered certain expenses on behalf of its Sponsor, paying $14,750 and $13,877 as of September 30, 2025 and December 31, 2024, respectively, of which such amount is included in due from related party in the accompanying condensed consolidated balance sheets.

NOTE 6. COMMITMENT AND CONTINGENCIES

Registration Rights Agreement

The holders of the Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of working capital loans (and any Class A ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants issued upon conversion of working capital loans) are entitled to registration rights pursuant to a registration rights agreement signed on the effective date of the registration statement. The holders of these securities are entitled to make up to three demands, excluding short form demands, that we register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to consummation of a business combination. We have granted Cantor and Odeon or their designees or affiliates certain registration rights relating to these securities. The underwriters of the Initial Public Offering may not exercise their demand and “piggyback” registration rights after five and seven years, respectively, after the effective date of the registration statement and may not exercise demand rights on more than one occasion. We bear the expenses incurred in connection with the filing of any such registration statements.

Underwriting Agreement

In connection with the Initial Public Offering, the underwriters were granted a 45-day option from the date of the prospectus to purchase up to 3,000,000 additional Units to cover over-allotments. On October 12, 2021, the underwriters fully exercised the over-allotment option to purchase an additional 3,000,000 Units at an offering price of $10.00 per Unit, generating additional gross proceeds of $30,000,000 to the Company.

The underwriters were paid a cash underwriting discount of $0.20 per Unit (excluding over-allotment Units) in the Initial Public Offering, or $4,000,000 in the aggregate, upon the closing of the Initial Public Offering. In addition, $0.50 per Unit (excluding over-allotment Units) and $0.70 per over-allotment Unit (totaling $12,100,000 in the aggregate) is payable to the underwriters for deferred underwriting commissions. The deferred fee is payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of that certain underwriting agreement, dated as of October 6, 2021 (the “Underwriting Agreement”).

On April 12, 2023, the Company entered into a fee reduction agreement (the “Fee Reduction Agreement”), which amends the Underwriting Agreement. According to the Underwriting Agreement, the Company previously agreed to pay to the underwriters of the Initial Public Offering an aggregate of $12,100,000 as deferred underwriting commissions, a portion of which fee is payable to each underwriter in proportion to their respective commitments pursuant to the Underwriting Agreement, upon the consummation of a Business Combination. Pursuant to the Fee Reduction Agreement, the underwriters have agreed to forfeit sixty-six and 94/100 percent (66.94%) of the aggregate deferred underwriting commissions of $12,100,000 for a total reduction of $8,100,000. However, if the Company enters into a Business Combination with a target at a pre-money valuation above $100 million, the forfeiture percentage for underwriters will be reduced to no less than fifty percent (50%) of the aggregate deferred underwriting commissions of $12,100,000 for an approximate reduction of $6,050,000.

On April 4, 2024, the Company entered into an Amended & Restated Fee Reduction Agreement, which amends the Underwriting Agreement with Cantor Fitzgerald & Co. (“CF&CO”). Pursuant to the Amended and Restated Fee Reduction Agreement with CF&CO, in the event that the Company consummates the Business Combination with AERKOMM, CF&CO agrees that it will forfeit $6,475,000 of the aggregate original deferred fee that would otherwise be payable by the Company to CF&CO, resulting in a remainder of $1,995,000. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a business combination, subject to the terms of the underwriting agreement.

21On April 4, 2024, we entered into an Amended & Restated Fee Reduction Agreement, which amends the Underwriting Agreement with Odeon Capital Group LLC (“Odeon”). Pursuant to the Amended and Restated Fee Reduction Agreement with Odeon, in the event that we consummates the Business Combination with AERKOMM, Odeon agrees that it will forfeit $2,775,000 of the aggregate original deferred fee that would otherwise be payable by us to Odeon, resulting in a remainder of $855,000.

Table of Contents

IX ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~September~~March 3031, ~~2025~~2026

On April 4, 2024, the Company entered into an Amended & Restated Fee Reduction Agreement, which amends the Underwriting Agreement with Odeon Capital Group LLC (“Odeon”). Pursuant to the Amended and Restated Fee Reduction Agreement with Odeon, in the event that the Company consummates the Business Combination with AERKOMM, Odeon agrees that it will forfeit $2,775,000 of the aggregate original deferred fee that would otherwise be payable by the Company to Odeon, resulting in a remainder of $855,000. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a business combination, subject to the terms of the underwriting agreement.

Merger Agreement

On March 29, 2024, the Company, a Cayman Islands exempted company (which will de-register from the Register of Companies in the Cayman Islands by way of continuation out of the Cayman Islands and into the State of Delaware so as to migrate to and domesticate as a Delaware corporation prior to the closing date) entered into a Merger Agreement, by and among the Company, AKOM Merger Sub Inc., a Nevada corporation and a wholly owned subsidiary of the Company (“Merger Sub”), and AERKOMM Inc., a Nevada corporation (the “AERKOMM”) (as it may be amended and/or restated from time to time, the “Merger Agreement”).

On September 25, 2024, the Company, Merger Sub and AERKOMM entered into an amendment to the Merger Agreement to (1) provide that any lock-up period applicable to the Sponsor or any officers, directors or affiliates of the Company will terminate at the closing of the Merger, (2) change the percentage of the Founder Shares being treated as Escrowed Sponsor Shares from 50% to 25%, (3) add a provision providing for AERKOMM to pay certain amounts to the Company to cover its working capital and extension expenses, and (4) add a provision that the Company may terminate the Merger Agreement at any time prior to the closing date if AERKOMM or any Subsidiary of AERKOMM enters into voluntary bankruptcy or fails to remove within 60 days any petition in bankruptcy filed against it prior to closing.

On April 12, 2025, the Company, Merger Sub and AERKOMM entered into a third amendment to the Merger Agreement (the “Amendment No. 3”) to amend and restate the termination term. Either the Company or AERKOMM may terminate the Merger Agreement if the closing ~~date~~has ~~term~~not occurred by April 17, 2025 (the “Outside Closing Date”), provided that the delay was not caused by the party seeking to terminate.

On June 12, 2025, ~~and~~ September 10, 2025, November 19, 2025 and December 19, 2025, AERKOMM wired $~~670~~150,000, ~~and~~$200,000, $~~300~~65,000 ofand ~~the~~$85,000, ~~proceeds~~respectively, ~~from SAFE Note Agreement No. 3~~ to the Company as partial repayment of the ~~account~~accounts receivable, ~~respectively.~~which ~~The~~relates ~~Company~~to ~~recognized~~target adelay ~~benefit~~charge ~~from~~that ~~credit~~AERKOMM ~~loss~~is ofobligated ~~$350,000~~to inpay ~~the~~under ~~accompanying~~SAFE ~~condensed~~Note ~~consolidated~~Agreements ~~statement of operations~~No. ~~As of September 30, 2025 and December 31, 2024, the Company recorded a $2,471,333 and $500,000 account receivable related to a target delay charge, respectively~~3. ~~Simultaneously,~~No abenefit ~~full~~from ~~allowance for~~ credit loss ofwas ~~$2,471,333~~recognized ~~and~~during ~~$500,000~~the ~~were~~three ~~recognized~~months asended ofMarch ~~September 30~~31, ~~2025~~2026 and ~~December 31, 2024~~2025.

As of March 31, 2026 and December 31, 2025, the Company recorded a $3,453,208 and $3,125,542 accounts receivable related to a target delay charge, respectively. Simultaneously, a full allowance for credit loss of $3,453,208 and $3,125,542 were recognized as of March 31, 2026 and December 31, 2025, respectively.

On January 8, 2026, the Company entered into an amendment to the Merger Agreement (the “Amendment No. 4”) whereby the Company will become a Delaware corporation by means of a merger of the Company with and into a newly formed Delaware corporation pursuant to the Cayman Islands Companies Law and the applicable provisions of the Delaware General Corporation Law, with such newly formed Delaware corporation becoming the surviving corporation in the merger.

The PIPE Investment

Concurrently with the execution of the Merger Agreement, the Company and AERKOMM entered into subscription agreements (the “Subscription Agreements”) with certain accredited investors providing for investments in ~~the Company~~AERKOMM’s ~~Common~~common ~~Stock~~stock in a private placement for an aggregate cash amount of $35,000,000 at $11.50 per share of the Company’s Common Stock (the “PIPE Investment”). AERKOMM will exercise reasonable best efforts to obtain a PIPE Investment Amount of at least $65,000,000 (inclusive of investment amounts under SAFE Agreements (as defined below)) pursuant to PIPE arrangements, and will obtain a minimum PIPE Investment Amount, unless waived by the Company, of at least $ 45,000,000 minus the investment amount obtained pursuant to SAFE Agreements (the “PIPE Minimum Investment Amount”) and will consummate the transactions contemplated by the Subscription Agreements.

2219

Table of Contents

IX ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~September~~March 3031, ~~2025~~2026

The SAFE Investment

On March 29, 2024, the Company entered into a Merger Agreement, by and among Merger Sub. and AERKOMM (as it may be amended and/or restated from time to time, the “Merger Agreement”). Pursuant to the Merger Agreement, the Company was obligated to enter into simple agreements for future equity (the “SAFE Agreements”) with certain investors providing for investments in shares of the ~~Company~~AERKOMM’s ~~Common~~common ~~Stock~~stock in a private placement in an aggregate amount of not less than $15,000,000 (exercising reasonable best efforts to secure $5,000,000 within twenty (20) ~~Business~~business ~~Days~~days of the date of the Merger Agreement, another $5,000,000 within forty (40) ~~Business~~business ~~Days~~days of the date of the Merger Agreement, and another $5,000,000 within sixty (60) ~~Business~~business ~~Days~~days of the date of the Merger Agreement) that will automatically convert upon the closing at $11.50 per share of the Company’s Common Stock and in accordance with such SAFE Agreements and the Merger Agreement (such investments in the aggregate, the “SAFE Investment”).

As of August 12, 2024, an aggregate of $2.6 million of SAFE Investment has been made. The SAFE Investment will initially be placed in an escrow account and may be released from such escrow account to an account of AERKOMM pursuant to the joint written instructions of AERKOMM and the Company.

On December 4, 2024, the Company and AERKOMM entered into one new SAFE Agreement. As a result, as of December 4, 2024, SAFE Agreements for an aggregate of $4,997,200· have been entered into. The SAFE Agreements will automatically convert upon the closing of the merger at $11.50 per share of the Company’s Common Stock. If the SAFE Agreements automatically convert upon the closing of the merger, in addition to 434,539 of the Company’s Common Stock, the SAFE Agreements are also convertible into an additional 94% of the number of shares of Company’s Common Stock, or 408,466 shares to be held in escrow subject to the same Milestone Events outlined in the Merger Agreement under the Incentive Merger Consideration (the “Incentive Shares”) section.

The Company analyzed the SAFE agreement under ASC 480 and ASC 815, noting that the Common Stock and Incentive Shares issuable under the SAFE Agreement do ~~NOT~~not ~~meets~~meet the requirements for equity classification. As a result, the Common Stock and Incentive Shares are required to be classified as a liability and measured at fair value with changes in fair value recorded in earnings,. ~~the~~The SAFE notes were issued by AERKOMM and as such the liability has been reflected in the unaudited condensed consolidated financial ~~statement~~statements of AERKOMM at issuance and as of ~~September~~March 3031, ~~2025~~2026.

On June 9, 2025, the Company and AERKOMM entered into a new SAFE Agreement (the “SAFE Note Agreement No. 3”). On July 23, 2025, the Company and AERKOMM entered into a new SAFE Agreement (the “SAFE Note Agreement No. 4”). On September 5, 2025, the Company and AERKOMM entered into a new SAFE Agreement (the “SAFE Note Agreement No. 4.2”). On October 23, 2025, the Company and AERKOMM entered into another SAFE Agreement (the “SAFE Note Agreement No. 5”). As a result, as of date that this Current Report on Form 10-Q has been filed, SAFE Agreements for an aggregate of $8,997,200 have been entered into. The SAFE Agreements will automatically convert upon the closing of the merger at $11.50 per share of the Company’s Common Stock. If the SAFE Agreements automatically convert upon the closing of the merger, in addition to 782,365 of the Company’s Common Stock, the SAFE Agreements are also convertible into an additional 94% of the number of shares of the Company’s Common Stock, or 735,423 shares to be held in escrow subject to the same Milestone Events outlined in the Merger Agreement under the Incentive Merger Consideration (the “Incentive Shares”) section.

On October 23, 2025, the Company and AERKOMM entered into another SAFE Agreement (the “SAFE Note Agreement No. 5”). As a result, as of the date that this Current Report on Form 10-Q has been filed, SAFE Agreements for an aggregate of $8,997,200 have been entered into. The SAFE Agreements will automatically convert upon the closing of the merger at $11.50 per share of the Company’s Common Stock. If the SAFE Agreements automatically convert upon the closing of the merger, in addition to 782,365 of the Company’s Common Stock, the SAFE Agreements are also convertible into an additional 94% of the number of shares of the Company’s Common Stock, or 735,423 shares to be held in escrow subject to the same Milestone Events outlined in the Merger Agreement under the Incentive Merger Consideration (the “Incentive Shares”) section.

Sponsor Support Agreement

In connection with the execution of the Merger Agreement, the Company entered into a support agreement (the “Sponsor Support Agreement”) with the Sponsor and AERKOMM, pursuant to which the Sponsor agreed to, among other things, (i) vote all of its shares in favor of each the Company Proposal sought by the Company with respect to the Merger Agreement or the transactions contemplated thereby, (ii) vote against any Alternative Proposal or proposal relating to a business combination transaction, (iii) vote against any merger agreement or merger, consolidation, combination, sale of substantial assets, reorganization, recapitalization, dissolution, liquidation or winding up of or by the Company (other than the Merger Agreement and transactions relating to the Merger), (iv) vote against any change in the business, management or the Board of Directors of the Company (other than in connection with the Merger), (v) vote against any proposal that would impede the Merger or that would result in a breach with respect to any obligation or agreement of the Company, Merger Sub or the Sponsor under the Merger Agreement or the Company Support Agreement, and (vi) vote in favor of any proposal to extend the period of time the Company is afforded under its organizational documents to consummate an initial business combination, in each case, subject to the terms and conditions of the Company Support Agreement.

2320

Table of Contents

IX ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~September~~March 3031, ~~2025~~2026

AERKOMM Support Agreement

In connection with the execution of the Merger Agreement, the Company entered into a support agreement (the “AERKOMM Support Agreement”) with AERKOMM and certain shareholders of AERKOMM (the “AERKOMM Supporting Shareholders”) pursuant to which the AERKOMM Supporting Shareholders agreed to, among other things, (i) vote to approve and adopt the Merger Agreement and the transactions contemplated thereby, including the Merger (“AERKOMM Transaction Proposals”); (ii) vote against any merger agreement or merger, consolidation, combination, sale of substantial assets, reorganization, recapitalization, dissolution, liquidation or winding up of or by AERKOMM (other than the Merger Agreement and the transactions relating to the Merger); (iii) vote against any change in the business (to the extent in violation of the Merger Agreement), management or Board of Directors of AERKOMM (other than in connection with AERKOMM Transaction Proposals and the transactions contemplated thereby); and (iv) vote against any proposal that would impede the Merger or that would result in a breach with respect to any obligation or agreement of AERKOMM or AERKOMM Securityholders under the Merger Agreement or the AERKOMM Support Agreement.

Registration Rights Agreement

The Merger Agreement contemplates that, at the closing, Pubco, the Sponsor and certain former shareholders of AERKOMM (collectively, the “Holders”) will enter into a registration rights agreement (the “Registration Rights Agreement”), pursuant to which Pubco will agree to register for resale, pursuant to Rule 415 under the Securities Act, certain the Company’s Common Shares and Domesticated the Company Warrants that are held by the Holders from time to time.

The Registration Rights Agreement amends and restates the registration rights agreement that was entered into the Company, the Sponsor and the other parties thereto in connection with the Company’s initial public offering. The Registration Rights Agreement will terminate on the earlier of (a) the five year anniversary of the date of the Registration Rights Agreement or (b) with respect to any Holder, on the date that such Holder no longer holds any Registrable Securities.

Capital Markets Advisory Agreement

On September 29, 2024, the Company and AERKOMM signed an engagement letter to appoint Benchmark to serve as a non-exclusive PIPE placement agent for a private placement of securities of approximately $30,000,000 or such other amount as will be determined by the parties. Upon successful completion of the private offering, the Company and AERKOMM will pay Benchmark 5% of the gross proceeds of any equity or equity linked securities raised in the private offering plus 2.5% of the gross proceeds of any equity or equity linked securities raised in the private offering from purchasers of securities not introduced by Benchmark, up to a cap of $400,000. Both the $35,000,000 in PIPE subscriptions and the SAFE Agreements will not be assessed with regard to non-Bench mark introductions.

On October 9, 2024, the Company and AERKOMM entered into an amendment with Benchmark that 2.5% of the gross proceeds of any equity or equity linked securities raised in the Offering from purchasers of securities not introduced by Benchmark, up to a cap of $400,000 total in Company Sourced Offering Fees. The Company-sourced Offering Fee shall not be assessed on the issuance of SAFE Agreements by AERKOMM, which represents a separate offering of a separate security. The Company-sourced Offering Fee shall also be assessed on the $35,000,000 in PIPE commitments already signed by the Company and AERKOMM, and subject to the $400,000 if Benchmark acts as a Placement Agent in respect of the transaction.

On November 26, 2024, the Company and AERKOMM entered into a second amendment with Benchmark that Benchmark shall be entitled to engage sub-placement agents in connection with the Offering. The Company and AERKOMM agree that any fees payable to sub-placement agents shall be in addition to the Company Sourced Offering Fee payable to Benchmark.

On December 9, 2024, the Company and AERKOMM entered into Sub Placement Agreement with Yuanta Securities (Hong Kong) Company Limited (“Yuanta”). In connection with its services under the Sub Placement Agreement, Yuanta may solicit potential investors for both the Company and AERKOMM. Benchmark agreed to pay Yuanta a sub-placement fee of an amount equal to three percent (3%) of gross sales proceeds received by the Company and AERKOMM attributed to securities placed by or solicited through Yuanta.

2421

Table of Contents

IX ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~September~~March 3031, ~~2025~~2026

Commercial Funding and Repayment Agreement

On July 15, 2025, the Company entered into a Commercial Funding and Repayment Agreement by and among the Sponsor and AERKOMM. (the “CFR Agreement”).

Pursuant to the ~~CFR~~Commercial Funding and Repayment Agreement, AERKOMM ~~committed~~agreed to ~~the~~fund ~~following: exercising best efforts to file its Form 10-K with~~ the ~~SEC~~Company ~~no later than July 21~~$130,000 ~~2025;~~for ~~closing~~working ~~the~~capital ~~SAFE~~needs ~~Note~~from ~~Agreement~~May ~~No. 4~~12, ~~in a principal amount not less than $1,500,000, no later than July 31,~~ 2025; ~~filing~~through ~~its~~December ~~first quarter Form 10-Q no later than July 21~~12, 2025; ~~and~~for ~~filing~~a ~~its~~total ~~second~~of ~~quarter Form 10-Q no later than August 15~~$910, ~~2025~~000.

On June 12, 2025, ~~AERKOMM~~September ~~wired~~10, ~~$520~~2025,~~000~~ ofOctober ~~the~~17, ~~proceeds~~2025, ~~from~~and ~~SAFE~~October ~~Note~~30, ~~Agreement~~2025, ~~No. 3 to fund~~ the Company’s ~~working~~received ~~capital~~$520,000, ~~needs~~$100,000, ~~from~~$40,000, ~~May~~and 12$90,000, ~~2025 through September 12~~respectively, ~~2025~~for ~~(the~~a ~~“Working~~total ~~Capital~~of ~~Financing”) and~~ $~~150~~750,000 ~~of the proceeds~~ from ~~SAFE~~AERKOMM ~~Note~~for ~~Agreement~~working Nocapital needs. 3The toCompany ~~the~~recognized ~~Company~~$910,000, asrepresenting ~~partial~~seven ~~repayment~~months of the ~~$452,500~~working incapital ~~payables prorated to May 12~~financing, ~~2025~~resulting ~~(including~~in $12160,~~500~~000 indue ~~late~~from ~~fees)~~AERKOMM toas ~~reimburse~~of ~~the~~December ~~working~~31, ~~capital~~2025. ~~and~~The ~~general~~amount ~~corporate~~recognized ~~expenses~~was ofrecorded ~~the~~as ~~Company~~a ~~(the~~reduction ~~“Working~~to ~~Capital~~operating ~~Accrued~~and ~~Invoices”).~~formation expenses.

~~Pursuant~~On toJanuary 7, 2026 and March 12, 2026, the ~~Commercial~~Company ~~Funding~~received $125,000 and ~~Repayment~~$260,000, ~~Agreement~~respectively, for a total of $385,000 from AERKOMM ~~agreed~~for toworking ~~fund~~capital needs, fully settling the outstanding balance as of December 31, 2025. During the three months ended March 31, 2026, the Company recognized $~~130~~390,000 ~~for~~of working capital ~~needs~~support from ~~May~~AERKOMM, 12representing $130,000 ~~2025~~per month for January through ~~September~~March 122026. Of the $385,000 ~~2025~~received ~~for~~from aAERKOMM ~~total~~during ofthe quarter, $~~520~~160,000. Onwas ~~June~~applied 12to the outstanding receivable as of December 31, 2025, and the ~~Company~~remaining ~~received~~ $~~520~~225,000 was applied toward the current quarter’s working capital support. As of March 31, ~~which~~2026, the remaining $165,000 of working capital support was recorded as ~~working~~Due ~~capital~~from ~~financing~~AERKOMM in the accompanying ~~unaudited~~ condensed consolidated balance sheets. The recognized working capital support was recorded as a reduction of operating and formation expenses.

Within two (2) business days following the closing of SAFE Note Agreement No. 3, AERKOMM wired $150,000 to the Company as a partial repayment of Working Capital Accrued Invoices, which the Company shall use to repay an equal amount of its outstanding Extension Promissory Notes. Within two (2) business days following receipt of the Working Capital Financing, the Company agreed to pay the $130,000 Bridge Financing to the Sponsor. On August 18, 2025, the Company repaid $280,000 of its outstanding Extension Promissory Notes to the Sponsor.

On September 10, 2025, AERKOMM wired $100,000 of the proceeds from SAFE Note Agreement No. 4 to fund the Company’s working capital needs. On September 10, 2025, the Company received $100,000, which was recorded as working capital financing in the accompanying unaudited condensed consolidated balance sheets.

Within two (2) business days of the closing of the SAFE Note Agreement No. 4, AERKOMM wired $200,000 to the Company as an additional repayment of the Working Capital Accrued Invoices. The Company used the $200,000 to repay an equal amount of its outstanding extension promissory notes. The Company received the funds on September 10, 2025 and repaid the Sponsor on the same date.

On June 12, 2025 and September 10, 2025, the Company received $520,000 and $100,000, respectively, from AERKOMM for working capital needs. The Company amortized $570,000, representing four and a half months of the working capital financing. As of September 30, 2025, the Company recorded $50,000 as working capital financing in the accompanying unaudited condensed consolidated balance sheets. The amortized amount was recorded as a reduction to operating and formation expenses.

NOTE 7. WARRANTS

As of ~~September~~March 3031, ~~2025~~2026 and December 31, ~~2024~~2025, there were an aggregate of 18,650,000 warrants outstanding, comprised of 11,500,000 Public Warrants and 7,150,000 Private Placement Warrants.

Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination and (b) 12 months from the closing of the Initial Public Offering. The Public Warrants will expire five years from the completion of a Business Combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.

The Company will not be obligated to deliver any Class A ordinary shares pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the Class A ordinary shares underlying the warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying the obligations described below with respect to registration. No warrant will be exercisable and the Company will not be obligated to issue Class A ordinary shares upon exercise of a warrant unless the Class A ordinary shares issuable upon such warrant exercise have been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will the Company be required to net cash settle any warrant.

2522

Table of Contents

IX ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~September~~March 3031, ~~2025~~2026

obligations described below with respect to registration. No warrant will be exercisable and the Company will not be obligated to issue Class A ordinary shares upon exercise of a warrant unless the Class A ordinary shares issuable upon such warrant exercise have been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will the Company be required to net cash settle any warrant.

The Company agreed that as soon as practicable, but in no event later than fifteen (15) business days after the closing of an initial Business Combination, the Company will use its best efforts to file with the SEC a registration statement for the registration, under the Securities Act, of the Class A ordinary shares issuable upon exercise of the warrants. The Company will use its best efforts to cause the same to become effective and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the warrants in accordance with the provisions of the warrant agreement. If a registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the sixtieth (60th) business day after the closing of an initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption. Notwithstanding the above, if the Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, and in the event the Company does not so elect, the Company will use its best efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available.

Once the warrants become exercisable, the Company may call the warrants for redemption:

●

in whole and not in part;

●

at a price of $0.01 per warrant;

●

upon not less than 30 days’ prior written notice of redemption (the “30-day redemption period”) to each warrant holder; and

●

if, and only if, the closing price of the ordinary shares equals or exceeds $18.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like and for certain issuances of Class A ordinary shares and equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination) for any 20 trading days within a 30-trading day period ending three business days before the Company sends to the notice of redemption to the warrant holders.

The Company will not redeem the warrants for cash unless an effective registration statement under the Securities Act covering the Class A ordinary shares issuable upon exercise of the warrants is effective and a current prospectus relating to those Class A ordinary shares is available throughout the 30-day redemption period, except if the warrants may be exercised on a cashless basis and such cashless exercise is exempt from registration under the Securities Act. If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if the Company is unable to register or qualify the underlying securities for sale under all applicable state securities laws.

If the Company calls the warrants for redemption as described above, Management will have the option to require all holders that wish to exercise warrants to do so on a “cashless basis.” In determining whether to require all holders to exercise their warrants on a “cashless basis,” Management will consider, among other factors, its cash position, the number of warrants that are outstanding and the dilutive effect on the Company’s shareholders of issuing the maximum number of Class A ordinary shares issuable upon the exercise of the warrants. In such event, each holder would pay the exercise price by surrendering the warrants for that number of Class A ordinary shares equal to the quotient obtained by dividing (x) the product of the number of Class A ordinary shares underlying the warrants, multiplied by the excess of the “fair market value” of the Class A ordinary shares over the exercise price of the warrants by (y) the fair market value. The “fair market value” will mean the average reported closing price of the Class A ordinary shares for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants.

2623

Table of Contents

IX ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~September~~March 3031, ~~2025~~2026

In addition, if (x) the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of an initial Business Combination at an issue price or effective issue price of less than $9.20 per Class A ordinary share (with such issue price or effective issue price to be determined in good faith by the Board of Directors and, in the case of any such issuance to the Initial Shareholders, and Anchor Investors, or their affiliates, without taking into account any Founder Shares held by the Initial Shareholders, and Anchor Investors or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of an initial Business Combination on the date of the consummation of an initial Business Combination (net of redemptions), and the volume weighted average trading price of the Class A ordinary shares during the 20 trading day period starting on the trading day after the day on which the Company consummates an initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price.

The Private Placement Warrants (including the Class A ordinary shares issuable upon exercise of the Private Placement Warrants) will not be transferable, assignable or salable until 30 days after the completion of an initial Business Combination (except, among other limited exceptions, to the officers and directors and other persons or entities affiliated with the initial purchasers of the Private Placement Warrants) and they will not be redeemable by the Company so long as they are held by the initial purchasers or their permitted transferees. The initial purchasers, or their permitted transferees, have the option to exercise the Private Placement Warrants on a cashless basis. Except as described herein, the Private Placement Warrants have terms and provisions that are identical to those of the Public Warrants. If the Private Placement Warrants are held by holders other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by the holders on the same basis as the Public Warrants.

The accounting treatment of derivative financial instruments requires that the Company record the warrants as derivative liabilities at fair value upon the closing of the Initial Public Offering. The Public Warrants have been allocated a portion of the proceeds from the issuance of the Units equal to their fair value. The warrant liabilities are subject to re-measurement at each balance sheet date. With each such re-measurement, the warrant liabilities will be adjusted to its current fair value, with the change in fair value recognized in the Company’s unaudited condensed consolidated statements of operations. The Company will reassess the classification at each balance sheet date. If the classification changes as a result of events during the period, the warrants will be reclassified as of the date of the event that causes the reclassification.

NOTE 8. CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS’ DEFICIT

Preference Shares

The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share with such designations, voting and other rights and preferences as may be determined from time to time by the Board of Directors. As of ~~September~~March 3031, ~~2025~~2026 and December 31, ~~2024~~2025, there were no preference shares issued or outstanding.

Class A Ordinary Shares

The Company is authorized to issue 200,000,000 Class A ordinary shares with a par value of $0.0001 per share. Holders of Class A ordinary shares are entitled to one vote for each share. As of ~~September~~March 3031, ~~2025~~2026 and December 31, ~~2024~~2025, there were 4,002,121 Class A ordinary shares issued and outstanding, excluding 1701,~~610,373~~043 shares of Class A ordinary shares subject to possible redemption, which are presented as temporary equity.

Class B Ordinary Shares

The Company is authorized to issue 20,000,000 Class B ordinary shares with a par value of $0.0001 per share. Holders of Class B ordinary shares are entitled to one vote for each share. As of ~~September~~March 3031, ~~2025~~2026 and December 31, ~~2024~~2025, there were 1,747,879 Class B ordinary shares issued and outstanding, ~~respectively,~~ and the Initial Shareholders, including the Anchor Investors, owned 67% of the Company’s issued and outstanding shares on an as-converted basis.

2724

Table of Contents

IX ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~September~~March 3031, ~~2025~~2026

Ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders. Except as described below, holders of Class A ordinary shares and holders of Class B ordinary shares vote together as a single class on all matters submitted to a vote of the Company’s shareholders, except as required by law. Unless specified in the Amended and Restated Memorandum and Articles of Association, or as required by applicable provisions of the Companies Act or applicable stock exchange rules, the affirmative vote of a majority of the ordinary shares that are voted is required to approve any such matter voted on by the shareholders. Approval of certain actions will require a special resolution under Cayman Islands law, being the affirmative vote of at least two-thirds of the ordinary shares that are voted, and pursuant to the Amended and Restated Memorandum and Articles of Association; such actions include amending the Amended and Restated Memorandum and Articles of Association and approving a statutory merger or consolidation with another company.

The Board of Directors is divided into three classes, each of which will generally serve for a term of three years with only one class of directors being appointed in each year. There is no cumulative voting with respect to the appointment of directors, with the result that the holders of more than 50% of the shares voted for the appointment of directors can appoint all of the directors. The Company’s shareholders are entitled to receive ratable dividends when, as and if declared by the Board of Directors out of funds legally available therefor. Prior to the Company’s initial Business Combination, (i) only holders of the Founder Shares will have the right to vote on the appointment of directors and (ii) in a vote to continue the Company in a jurisdiction outside the Cayman Islands (which requires the approval of at least two thirds of the votes of all ordinary shares), holders of the Class B ordinary shares will have ten votes for every Class B ordinary share and holders of the Class A ordinary shares will have one vote for every Class A ordinary share. These provisions of the Amended and Restated Memorandum and Articles of Association may only be amended by a special resolution passed by not less than 90% of the ordinary shares who attend and vote at the Company’s general meeting which shall include the affirmative vote of a simple majority of the Class B ordinary shares. Holders of the Public Shares will not be entitled to vote on the appointment of directors prior to the initial Business Combination. In addition, prior to the completion of an initial Business Combination, holders of a majority of the Founder Shares may remove a member of the Board of Directors for any reason. In connection with the initial Business Combination, the Company may enter into a shareholders agreement or other arrangements with the shareholders of the target with respect to voting and other corporate governance matters following completion of the initial Business Combination.

NOTE 9. FAIR VALUE MEASUREMENTS

The following table presents information about the Company’s financial assets that are measured at fair value on a recurring basis as of ~~September~~March 3031, ~~2025~~2026 and December 31, ~~2024~~2025, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:

Amount at Fair

Description

Value

Level 1

Level 2

Level 3

September 30, 2025

March 31, 2026

Liabilities

Warrant liability – Public Warrants

1575,~~725,~~000

—

1575,~~725,~~000

—

Warrant liability – Private Placement Warrants

1357,~~072,~~500

—

1357,~~072,~~500

Total Liabilities

2932,~~797,~~500

—

1575,~~725,~~000

1357,~~072,~~500

Amount at Fair

Description

Value

Level 1

Level 2

Level 3

December 31, 2024

December 31, 2025

Liabilities

Warrant liability – Public Warrants

~~690~~1,725,000

—

~~690~~1,725,000

—

Warrant liability – Private Placement Warrants

~~429~~1,~~000~~072,500

—

~~429~~1,~~000~~072,500

Total Liabilities

12,~~119~~797,~~000~~500

—

~~690~~1,725,000

~~429~~1,~~000~~072,500

Cash Held in Trust Account

As of ~~September~~March 3031, ~~2025,~~2026 ~~assets~~and ~~held in the Trust Account were comprised of approximately $19.8 million in cash held by Trust Account. As of~~ December 31, ~~2024~~2025, assets held in the Trust Account were comprised of approximately $188.9 million and $8.8 million in cash held by Trust Account, respectively.

2825

Table of Contents

IX ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~September~~March 3031, ~~2025~~2026

Fair Value Measurements

Transfers to/from Levels 1, 2 and 3 are recognized at the end of the reporting period. The estimated fair value of the Public Warrants transferred from a Level 3 measurement to a Level 1 fair value measurement in November 2021, when the Public Warrants were separately listed and traded, and subsequently transferred to a Level 2 measurement during the quarter ended March 31, 2022 due to low trading volume.

The Company utilized a Monte-Carlo simulation model for the initial valuation of the Public Warrants. Beginning in November 2021, the fair value of Public Warrants has been measured based on the listed market price of such Public Warrants under the ticker “IXAQW”.

On December 10, 2024, the Company received a notice from the Panel acknowledging that the Company had withdrawn its appeal of the October 7, 2024 delist determination issued by the Nasdaq. Accordingly, trading in the Company’s securities was suspended at the open of trading on December 12, 2024. On June 6, 2025, the Company filed a Form 25 Notification of Delisting with the SEC which removed the Company’s securities from on the Nasdaq Stock Market. The Company’s Common Stock, Units and Warrants began to be quoted on the Pink Markets operated on The OTC Market systems (“OTC Market”) under the symbols “IXQUF,” “IXAQF” and “IXQWF.”

The Company ~~utilized~~utilizes a probability-adjusted Black-Scholes method to value the Private Placement Warrants at each reporting period, with changes in fair value recognized in the unaudited condensed consolidated statements of operations. The estimated fair value of the Private Placement Warrant liabilities is determined using Level 3 inputs. Inherent in pricing models are assumptions related to expected share-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its ordinary shares based on historical volatility that matches the expected remaining life of the warrants. The risk-free interest rate is based on the Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates to remain at zero.

The following table provides the significant inputs to the probability-adjusted Black-Scholes method for the fair value of the Private Placement Warrants:


	~~September~~March 3031, ~~2025~~2026			December 31, ~~2024~~2025
Stock price	$	12.2006		$	1112.5506
Exercise price	$	11.50		$	11.50
Dividend yield		—	%		—	%
Expected term (in years)		65.0353			5.78
Volatility		2.2000	%		32.0020	%
Risk-free rate		3.7789	%		43.3274	%
Fair value	$	0.1505		$	0.0615
Probability of Business Combination		41.9080	%		25.340	%

The following table provides a summary of the changes in the fair value of the Company’s Level 3 financial instruments that are measured at fair value on a recurring basis:


Fair value at December 31, 2025	$	1,072,500
Change in fair value of Private Placement Warrants		(715,000)
Fair value at March 31, 2026	$	357,500

Fair value at December 31, 2024	$	429,000
Change in fair value of Private Placement Warrants		(143,000)
Fair value at March 31, 2025	$	286,000

Table of Contents

IX ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~September~~March 3031, ~~2025~~2026

The ~~following~~Company ~~table~~recognized ~~provides~~$1,865,000 again ~~summary~~and of$373,000 ~~the~~gain ~~changes~~on change in the fair value of the ~~Company’s~~Public ~~Level~~Warrants 3and ~~financial~~Private ~~instruments~~Placement ~~that~~Warrants ~~are~~in ~~measured~~the ataccompanying ~~fair~~unaudited ~~value~~condensed onconsolidated astatements ~~recurring~~of ~~basis:~~operations for the three month period ended March 31, 2026 and 2025, respectively.


Fair value at December 31, 2024	$	429,000
Change in fair value of Private Placement Warrants		(143,000)
Fair value at March 31, 2025	$	286,000
Change in fair value of Private Placement Warrants		286,000
Fair value at June 30, 2025	$	572,000
Change in fair value of Private Placement Warrants		500,500
Fair value at September 30, 2025	$	1,072,500

Fair value at December 31, 2023	$	143,000
Change in fair value of Private Placement Warrants		71,500
Fair value at March 31, 2024	$	214,500
Change in fair value of Private Placement Warrants		357,500
Fair value at June 30, 2024	$	572,000
Change in fair value of Private Placement Warrants		—
Fair value at September 30, 2024	$	572,000

The Company recognized $1,305,500 loss and $0 loss on change in the fair value of the Public Warrants and Private Placement Warrants in the accompanying statements of operations for the three months period ended September 30, 2025 and 2024, respectively. The Company recognized $1,678,500 loss and $1,119,000 loss on change in the fair value of the Public Warrants and Private Placement Warrants in the accompanying statements of operations for the nine months period ended September 30, 2025 and 2024, respectively.

Derivative Liability-Conversion Feature

The Company utilizes a Monte Carlo model to estimate the fair value of the conversion feature within the Extension Promissory Note, which is required to be recorded at its initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the conversion feature are recognized as non-cash gains or losses in the accompanying unaudited condensed consolidated statements of operations.

The key assumptions in the model relate to expected share-price volatility, risk-free interest rate, exercise price, expected term and the probability of occurrence of the transaction. The expected volatility was based on the average volatility of special purpose acquisition companies that are searching for an acquisition target. The risk-free interest rate is based on interpolation of Treasury yields with a term commensurate with the term of the warrants. The Company anticipates the dividend yield to be zero. The expected term of the warrants is assumed to be the estimated date of a Business Combination.

The estimated fair value of the conversion feature related to the Extension Promissory Note as of issuance and for the ~~period~~periods ended ~~September~~March 3031, 2026 and 2025 is zero.

NOTE 10. SEGMENT INFORMATION

ASC Topic 280, “Segment Reporting,” establishes standards for companies to report in their unaudited condensed consolidated financial statements information about operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise for which separate financial information is available that is regularly evaluated by the Company’s chief operating decision maker, or group, in deciding how to allocate resources and assess performance.

The Company’s chief operating decision maker has been identified as the Chief Executive Officer and Chief Financial Officer (“CODM”), who reviews the operating results for the Company as a whole to make decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the Company only has one operating segment. The CODM assesses performance for the single segment and decides how to allocate resources based on net income that also is reported on the unaudited condensed consolidated statement of operations as net income. The measure of segment assets is reported on the condensed consolidated balance sheet as total assets. When evaluating the Company’s performance and making key decisions regarding resource allocation, the CODM reviews several key metrics included in net income and total assets, which include the following:

Table of Contents

IX ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2025

The CODM assesses performance for the single segment and decides how to allocate resources based on net loss that also is reported on the condensed consolidated statement of operations as net loss. The measure of segment assets is reported on the condensed consolidated balance sheet as total assets. When evaluating the Company’s performance and making key decisions regarding resource allocation, the CODM reviews several key metrics included in net loss and total assets, which include the following:


	~~September~~March 3031,		December 31,
	~~2025~~2026		~~2024~~2025
Trust Account	$	198,~~846~~926,~~616~~816	$	188,~~949~~781,~~539~~221
Cash	$	85373,~~883~~452	$	3178,~~527~~975


		For the Three			For the ~~Nine~~Three
		Months Ended			Months Ended
		~~September~~March 3031,			~~September~~March 3031,
	~~ ~~	~~2025~~2026		~~ ~~	2025
Operating and formation (income) expenses		$	(~~177~~35,~~733~~413)		$	~~178~~281,~~463~~488
Interest earned on the Trust Account		$	~~157~~61,~~109~~470		$	~~462~~150,~~276~~613


	For the Three		For the Nine
	Months Ended		Months Ended
	September 30,		September 30,
	2024		2024
Operating and formation expenses	$	630,844	$	2,241,314
Interest earned on the Trust Account	$	349,967	$	1,039,879

The CODM reviews interest earned on the Trust Account to measure and monitor shareholder value and determine the most effective strategy of investment with the Trust Account funds while maintaining compliance with the Trust Agreement.27

Operating and formation expenses are reviewed and monitored by the CODM to manage and forecast cash to ensure enough capital is available to complete a business combination or similar transaction within the business combination period. The CODM also reviews operating and formation costs to manage, maintain and enforce all contractual agreements to ensure costs are aligned with all agreements and budget. Operating and formation costs, as reported on the consolidated statement of operations, are the significant segment expenses provided to the CODM on a regular basis.

All other segment items included in net loss are reported on the consolidated statement of operations and described within their respective disclosures.

Table of Contents

IX ACQUISITION CORP.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~September~~March 3031, ~~2025~~2026

Operating and formation expenses are reviewed and monitored by the CODM to manage and forecast cash to ensure enough capital is available to complete a business combination or similar transaction within the business combination period. The CODM also reviews operating and formation costs to manage, maintain and enforce all contractual agreements to ensure costs are aligned with all agreements and budget. Operating and formation costs, as reported on the unaudited condensed consolidated statement of operations, are the significant segment expenses provided to the CODM on a regular basis.

All other segment items included in net income are reported on the unaudited condensed consolidated statement of operations and described within their respective disclosures.

NOTE 11. SUBSEQUENT EVENTS

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the accompanying unaudited condensed consolidated financial statements were issued. Based upon this review, other than below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the accompanying unaudited condensed consolidated financial statements.

On ~~October~~April 621, ~~2025~~2026, ~~the~~June ~~Company~~8, ~~entered~~2026, ~~into~~July a1, ~~Returned~~2026 ~~Capital~~and ~~Agreement~~July ~~with~~14, 2026, the ~~Sponsor~~Company ~~and~~made anfour ~~Investor~~deposits ~~related~~of to$28,042 each into the ~~Subscription~~Company’s ~~Agreement~~trust ~~dated~~account ~~October~~in 1connection with April,~~2021.~~ ~~The~~May, ~~agreement~~June ~~provides~~and ~~for~~July 2026 extension contributions to extend the ~~return~~life ofuntil ~~certain~~May ~~capital~~12, ~~originally~~2026, ~~invested~~June ~~under~~12, ~~that~~2026, ~~Subscription~~July ~~Agreement~~12, 2026 and August 12, 2026, respectively.

On ~~October~~June 1030, ~~2025~~2026, the Company ~~held~~repaid an extraordinary general meeting of its shareholders. At the meeting, the Fourth Extension Amendment Proposal to give the Board the right to extend the date by which the Company must consummate a Business Combination from October 12, 2025 on a monthly basis up to twelve (12) times until October 12, 2026 was approved by depositing into the Company’s trust account for each one-month extension the lesser of (a) $40150,000 ~~and~~of ~~(b)~~the ~~$0.04 for each then~~ outstanding ~~share~~Promissory ~~after~~Note ~~giving effect~~ to ~~any redemptions. In connection with~~ the ~~extraordinary general meeting, 909,330 shares were tendered for redemption for cash at an approximate price of $12~~Sponsor.~~34 per share, for an aggregate of approximately $11.2 million.~~

On October 23, 2025, the Company and AERKOMM entered into another SAFE Agreement (the “SAFE Note Agreement No. 5”).

On November 4, 2025, November 18, 2025 and December 19, 2025, the Company made three deposits of $28,042 each into the Company’s trust account in connection with November, December and January 2026 extension contributions to extend the life until November 12, 2025, December 12, 2025 and January 12, 2026, respectively.

3228

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Cautionary Note Regarding Forward-Looking Statements

All statements other than statements of historical fact included in this quarterly report on Form 10-Q (this “Report”) including, without limitation, statements in this section regarding our financial position, business strategy and the plans and objectives of Management for future operations, are forward-looking statements. When used in this Report, words such as “anticipate,” “believe,” “estimate,” “expect,” “intend” and similar expressions, as they relate to us or our Management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of our Management, as well as assumptions made by, and information currently available to, our Management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in our filings with the SEC. All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements and the notes thereto included in this Report under “Item 1. Financial Statements”.

Overview

We are a blank check company incorporated on March 1, 2021 as a Cayman Islands exempted company for the purpose of effecting a business combination. WeOn ~~have~~March ~~not~~29, ~~selected any business combination target~~2024, ~~but~~ we ~~have~~entered ~~had~~into ~~substantive~~an ~~discussions~~Agreement ~~with~~and ~~potential~~Plan ~~business~~of ~~combination~~Merger ~~targets. We intend to effectuate our initial business combination using cash from~~ (the ~~proceeds~~“Merger ofAgreement”) ~~our~~with ~~Initial~~AERKOMM ~~Public Offering~~ and the ~~private~~other ~~placement~~parties thereto, ~~the~~pursuant ~~proceeds~~to ofwhich ~~the~~we ~~sale~~intend ofto ~~our~~consummate ~~shares in connection with~~ our initial business combination ~~pursuant~~with ~~to the forward purchase agreements (or backstop agreements we may enter into or otherwise)~~AERKOMM, ~~shares~~subject ~~issued~~ to the ~~owners~~satisfaction ~~of the target, debt issued to bank~~ or ~~other~~waiver ~~lenders or the owners~~ of the ~~target,~~conditions orset aforth ~~combination~~in of the ~~foregoing~~Merger ~~or other sources~~Agreement.

We intend to consummate the proposed business combination using cash from the proceeds of our Initial Public Offering and the private placement, proceeds from the sale of our securities in connection with the proposed business combination pursuant to forward purchase agreements, backstop agreements or similar arrangements that we may enter into, equity securities issued to the owners of AERKOMM, debt issued to banks, other lenders or the owners of AERKOMM, or a combination of the foregoing and other sources.

The registration statement was declared effective on October 6, 2021. On October 12, 2021, we consummated the Initial Public Offering of 23,000,000 Units, including 3,000,000 Units that were issued pursuant to the underwriters’ exercise of their over-allotment option in full, at $10.00 per Unit, generating total gross proceeds of $230,000,000.

Simultaneously with the closing of the Initial Public Offering, we consummated the sale of 7,150,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant in the private placement to our sponsor, Cantor and Odeon generating gross proceeds of $7,150,000.

Upon the closing of the Initial Public Offering on October 12, 2021, an amount of $231,150,000 from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants in the private placement was placed in the Trust Account and was initially invested only in Treasury obligations with maturities of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act, which invest only in direct Treasury obligations. To mitigate the risk that we might be deemed to be an investment company for purposes of the Investment Company Act, on November 13, 2023 we instructed Continental to liquidate the investments held in the Trust Account and instead to hold the funds in the Trust Account in an interest-bearing demand deposit account at a bank, with Continental continuing to act as trustee, until the earliest of: (i) the completion of the initial business combination; (ii) the redemption of any public shares properly tendered in connection with a shareholder vote to amend the Amended and Restated Memorandum and Articles of Association to modify the substance or timing of our obligation to redeem 100% of the public shares if we do not complete the initial business combination within the Combination Period; and (iii) absent an initial business combination within the Combination Period, the return of the funds held in the Trust Account to the Public Shareholders as part of the redemption of the public shares.

The Merger Agreement

On March 29, 2024, the Company entered into a Merger Agreement, by and among the Company, AKOM Merger Sub Inc., a Nevada corporation and a wholly owned subsidiary of the Company (“Merger Sub”), and AERKOMM Inc., a Nevada corporation (“AERKOMM”) (as it may be amended and/or restated from time to time, the “Merger Agreement”).

~~The parties to the Merger Agreement have made customary representations, warranties and covenants.~~29

Table of Contents

The parties to the Merger Agreement have made customary representations, warranties and covenants.

Amendments to the Merger Agreement

On September 25, 2024, the Company, Merger Sub and AERKOMM entered into an amendment to the Merger Agreement to (1) provide that any lock-up period applicable to the sponsor or any officers, directors or affiliates of the Company will terminate at the closing of the merger, (2) change the percentage of the Founder Shares being treated as escrowed sponsor shares from 50% to 25%, (3) add a provision providing for ~~the~~AERKOMM ~~Company~~ to pay certain amounts to the Company to cover its working capital and extension expenses, and (4) add a provision that the Company may terminate the Merger Agreement at any time prior to the closing date if AERKOMM or any subsidiary of AERKOMM enters into voluntary bankruptcy or fails to remove within 60 days any petition in bankruptcy filed against it prior to closing.

On February 12, 2025, the Company, Merger Sub and AERKOMM entered into a second amendment to the Merger Agreement to amend and restate the definitions of both “Indebtedness” and “Working Capital”.

On April 12, 2025, the Company, ~~Merger Sub~~ and AERKOMM entered into a third amendment to the Merger Agreement ~~(the~~in ~~“Amendment~~which NoSection 10.1 ~~3”)~~was toamended ~~amend~~ and ~~restate the closing date term~~restated.

On January 8, 2026, the Company and AERKOMM entered into a fourth amendment to the Merger Agreement in which the Company became a Delaware corporation by means of a merger with and into a newly formed Delaware corporation, AKOM Inc., pursuant to the Cayman Islands Companies Law and the applicable provisions of the DGCL, with AKOM Inc. becoming the surviving corporation in the merger. Consequently, if the Merger Agreement is approved by the Company’s shareholders, the Company will re-domicile into the State of Delaware and become a Delaware corporation by way of a merger of the Company with and into AKOM Inc.

Agreements Related to the Merger Agreement

Sponsor Support Agreement

In connection with the execution of the Merger Agreement, the Company entered into the Sponsor Support Agreement with the sponsor, pursuant to which the sponsor agreed to, among other things, (i) vote all of its shares in favor of each Company proposal sought by the Company with respect to the Merger Agreement or the transactions contemplated thereby, (ii) vote against any alternative proposal or proposal relating to a business combination transaction, (iii) vote against any merger agreement or merger, consolidation, combination, sale of substantial assets, reorganization, recapitalization, dissolution, liquidation or winding up of or by the Company (other than the Merger Agreement and transactions relating to the Merger), (iv) vote against any change in the business, management or board of directors of the Company (other than in connection with the merger), (v) vote against any proposal that would impede the merger or that would result in a breach with respect to any obligation or agreement of the Company, Merger Sub or the sponsor under the Merger Agreement or the Sponsor Support Agreement, and (vi) vote in favor of any proposal to extend the period of time the Company is afforded under its organizational documents to consummate an initial business combination, in each case, subject to the terms and conditions of the Sponsor Support Agreement.

In addition, the sponsor agreed to be bound by exclusivity and publicity sections of the Merger Agreement.

AERKOMM Support Agreement

In connection with the execution of the Merger Agreement, the Company, AERKOMM and certain shareholders of AERKOMM entered into the AERKOMM Support Agreement pursuant to which the AERKOMM supporting shareholders agreed to, among other things,(i) vote to approve and adopt the Merger Agreement and the transactions contemplated thereby, including the merger (“AERKOMM Transaction Proposals”); (ii) vote against any merger agreement or merger, consolidation, combination, sale of substantial assets, reorganization, recapitalization, dissolution, liquidation or winding up of or by AERKOMM (other than the Merger Agreement and the transactions relating to the merger); (iii) vote against any change in the business (to the extent in violation of the Merger Agreement), management or board of directors of AERKOMM (other than in connection with AERKOMM Transaction Proposals and the transactions contemplated thereby); and (iv) vote against any proposal that would impede the merger or that would result in a breach with respect to any obligation or agreement of AERKOMM or the AERKOMM securityholders under the Merger Agreement or AERKOMM Support Agreement.

Table of Contents

In addition, AERKOMM Supporting Shareholders agreed to be bound by exclusivity and publicity sections of the Merger Agreement.

The PIPE Investment

Concurrently with the execution of the Merger Agreement, the Company and AERKOMM entered into subscription agreements (the “Subscription Agreements”) with certain accredited investors providing for investments in AERKOMM’s common stock in a private placement for an aggregate cash amount of $35,000,000 at $11.50 per share of AERKOMM’s common stock (the “PIPE Investment”).

34AERKOMM will exercise reasonable best efforts to obtain a PIPE Investment Amount of at least $65,000,000 (inclusive of investment amounts under SAFE Agreements (as defined below)) pursuant to PIPE arrangements, and will obtain a minimum PIPE Investment Amount, unless waived by the Company, of at least $45,000,000 minus the investment amount obtained pursuant to SAFE Agreements and will consummate the transactions contemplated by the Subscription Agreements on the terms described therein.

Table of Contents

AERKOMM will exercise reasonable best efforts to obtain a PIPE Investment Amount of at least $65,000,000 (inclusive of investment amounts under SAFE Agreements (as defined below)) pursuant to PIPE arrangements, and will obtain a minimum PIPE Investment Amount, unless waived by the Company, of at least $ 45,000,000 minus the investment amount obtained pursuant to SAFE Agreements and will consummate the transactions contemplated by the Subscription Agreements on the terms described therein.

The SAFE Investment

Pursuant to the Merger Agreement, AERKOMM will enter into simple agreements for future equity, in the form and substance as reasonably agreed upon by the Company and AERKOMM (the “SAFE Agreements”), with certain investors providing for investments in shares of AERKOMM common stock in a private placement in an aggregate amount not less than $15,000,000 (exercising reasonable best efforts to secure $5,000,000 within twenty (20) business days of the date of the Merger Agreement, another $5,000,000 within forty (40) business days of the date of the Merger Agreement, and another $5,000,000 within sixty (60) business days of the date of the Merger Agreement) that will automatically convert ~~upon~~into ~~the closing at $11.50 per share of~~ Company ~~common~~Common ~~stock~~Stock and in accordance with such SAFE Agreements and the Merger Agreement (the “SAFE Investment”).

As of August 12, 2024, an aggregate of $2.6 million of SAFE Investment has been made. The SAFE Investment will initially be placed in an escrow account and may be released from such escrow account to an account of the Company pursuant to the joint written instructions of the Company and AERKOMM.

On December 4, 2024, the Company and AERKOMM entered into one new SAFE Agreement. As a result, as of December 4, 2024, SAFE Agreements for an aggregate of $4,997,200 have been entered into. If the SAFE Agreements automatically convert upon the closing of the merger, in addition to 434,539 of Company common stock, the SAFE Agreements are also convertible into an additional 94% of the number of shares of Company common stock, or 408,466 shares to be held in escrow subject to the same milestone events outlined in the Merger Agreement under the Incentive Merger Consideration section.

On June 9, 2025, the Company and AERKOMM entered into a new SAFE Agreement (the “SAFE Note Agreement No. 3”). On July 23, 2025, the Company and AERKOMM entered into a new SAFE Agreement (the “SAFE Note Agreement No. 4”). On September 5, 2025, the Company and AERKOMM entered into a new SAFE Agreement (the “SAFE Note Agreement No. 4.2”). On October 23, 2024, the Company and AERKOMM entered into a new SAFE Agreement (the “SAFE Note Agreement No. 5”). As a result, as of date that this Current Report on Form 10-Q has been filed, SAFE Agreements for an aggregate of $8,997,200 have been entered into. The SAFE Agreements will automatically convert upon the closing of the merger at $11.50 per share of the Company’s Common Stock. If the SAFE Agreements automatically convert upon the closing of the merger, in addition to 782,365 of the Company’s Common Stock, the SAFE Agreements are also convertible into an additional 94% of the number of shares of the Company’s Common Stock, or 735,423 shares to be held in escrow subject to the same Milestone Events outlined in the Merger Agreement under the Incentive Merger Consideration (the “Incentive Shares”) section.

On October 23, 2025, the Company and AERKOMM entered into a new SAFE Agreement (the “SAFE Note Agreement No. 5”). As a result, as of March 31, 2026, SAFE Agreements for an aggregate of $8,997,200 have been entered into. The SAFE Agreements will automatically convert upon the closing of the merger at $11.50 per share of IXAQ’s Common Stock. If the SAFE Agreements automatically convert upon the closing of the merger, in addition to 782,365 of IXAQ’s Common Stock, the SAFE Agreements are also convertible into an additional 94% of the number of shares of IXAQ’s Common Stock, or 735,423 shares to be held in escrow subject to the same Milestone Events outlined in the Merger Agreement under the Incentive Merger Consideration (the “Incentive Shares”) section.

Capital Markets Advisory Agreement

Table of Contents

Commercial Funding and Repayment Agreement

On July 15, 2025, the Company entered into a Commercial Funding and Repayment Agreement by and among the Sponsor and AERKOMM. (the “CFR Agreement”).

Pursuant to the CFR Agreement, AERKOMM ~~committed~~agreed to ~~the~~fund ~~following: exercising best efforts to file its Form 10-K with~~ the ~~SEC~~Company ~~no later than July 21~~$130,000 ~~2025;~~for ~~closing~~working ~~the~~capital ~~SAFE~~needs ~~Note~~from ~~Agreement~~May ~~No. 4~~12, ~~in a principal amount not less than $1,500,000, no later than July 31,~~ 2025; ~~filing~~through ~~its~~December ~~first quarter Form 10-Q no later than July 21~~12, 2025; ~~and~~for ~~filing~~a ~~its~~total ~~second~~of ~~quarter Form 10-Q no later than August 15~~$910, ~~2025~~000.

On September 10, 2025, AERKOMM wired $100,000 of the proceeds from SAFE Note Agreement No. 4 to fund the Company’s working capital needs On September 10, 2025, the Company received $100,000, which was recorded as working capital financing in the accompanying unaudited condensed consolidated balance sheets.

Extension of Our Combination Period

On April 10, 2023, we held the April 2023 Extraordinary Meeting, at which, our shareholders approved, among other things: (i) the Extension Proposal; (ii) the Redemption Limitation Amendment Proposal; and (iii) the Founder Share Amendment Proposal. Under Cayman Islands law, the amendments to the Amended and Restated Memorandum and Articles of Association took effect upon approval of the Extension Proposal, Founder Share Amendment Proposal and Redemption Limitation Amendment Proposal.

In connection with the votes to approve the Extension Proposal, the Redemption Limitation Amendment Proposal and the Founder Share Amendment Proposal, the holders of 18,336,279 Class A ordinary shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $10.31 per share, for an aggregate redemption amount of approximately $189 million. After the satisfaction of the Redemptions, the balance in the Trust Account was approximately $48 million.

36On April 13, 2023, May 9, 2023, June 9, 2023, July 11, 2023, August 9, 2023, September 7, 2023, October 12, 2023 and November 13, 2023, the Company announced that the Board of Directors has elected to extend the date by which the Company has to consummate a business combination from June 12, 2023 for an additional month to February 12, 2024. In connection with the third extension, the Board of Directors delivered the sponsor a written request to draw down $160,000 under its previously-disclosed promissory note for the third extension. On April 26, 2023, May 15, 2023, June 15, 2023, July 13, 2023, August 15, 2023, September 12, 2023, October 16,

Table of Contents

~~cash~~2023 atand aNovember ~~redemption~~30, ~~price~~2023, ofthe ~~approximately~~Sponsor ~~$10.31~~deposited ~~per share~~$160,000 ~~for~~into anthe ~~aggregate~~Company’s ~~redemption~~Trust ~~amount~~Account ofin ~~approximately~~connection ~~$189~~with ~~million. After~~ the ~~satisfaction~~first, ofsecond, ~~the~~third, ~~Redemptions~~fourth, ~~the~~fifth, ~~balance~~sixth, inseventh ~~the~~and ~~Trust~~eighth ~~Account was approximately $48 million~~extension.

AsOn ~~disclosed~~January in19, ~~the~~2024, ~~definitive proxy statement filed by~~ the Company ~~with~~announced that the ~~SEC~~Board onof ~~March~~Directors ~~23,~~has ~~2023,~~elected ~~relating~~ to ~~the~~extend ~~extraordinary general meeting of shareholders,~~ the ~~sponsor~~date ~~agreed~~by ~~that~~which if the ~~Extension~~Company ~~Proposal~~has isto ~~approved,~~consummate ita orbusiness ~~its~~combination ~~designee~~from ~~will~~January ~~deposit~~12, ~~into~~2024 ~~the~~for ~~Trust~~an ~~Account~~additional ~~established~~month into ~~connection~~February ~~with~~12, ~~the~~2024. The Company’s ~~Initial~~Amended ~~Public~~and ~~Offering~~Restated asMemorandum aand ~~loan,~~Articles anof ~~amount~~Association ~~equal~~provides to the ~~lesser~~Company ofwith ~~(x)~~the ~~$160,000~~right orto ~~(y)~~extend ~~$0.04~~the ~~per~~date ~~public~~eighteen ~~share~~times ~~multiplied~~for byan ~~the~~additional ~~number~~one ofmonth ~~public~~each ~~shares outstanding~~time, onfrom ~~each of the following dates: (i)~~ April 1312, 2023;, ~~and~~the ~~(ii)~~initial ~~one~~date, ~~business~~to ~~day~~up ~~following~~to ~~the~~October ~~public~~12, ~~announcement~~2024. byThe ~~the~~Board ~~Company~~of ~~disclosing~~Directors ~~that~~furthermore ~~the~~confirmed ~~board~~their ofintention ~~directors~~and ofpolicy ~~the~~to ~~Company~~continue ~~has determined~~ to extend the ~~Deadline~~dateon ~~Date~~a ~~(as~~monthly ~~defined~~basis, ~~below)~~but ~~for~~will annot ~~additional~~announce every month. inIn ~~accordance with~~ the ~~extension.~~event Onthat ~~April~~the ~~13,~~Board ~~2023,~~of ~~the~~Directors ~~sponsor~~elects ~~advanced~~not ~~$160,000~~ to ~~the~~extend, ~~Company~~they ~~for~~will ~~the~~announce ~~first~~this ~~month~~change ofin ~~extension~~policy.

OnIn ~~May~~connection 9,with ~~2023,~~ the ~~Company~~vote ~~announced that the board has elected~~ to ~~extend~~approve the ~~date~~Second byExtension ~~which~~Amendment ~~the~~Proposal, ~~Company has to consummate a business combination (~~the ~~“Deadline~~holders ~~Date”)~~of ~~from May 12~~1, ~~2023 for an additional month to June 12~~817,650 ~~2023.~~public ~~The~~shares ~~Company’s~~properly ~~Amended~~exercised ~~and~~their ~~Restated Memorandum and Articles of Association provides the Company the~~ right to ~~extend~~redeem ~~the~~such ~~Deadline~~shares ~~Date twelve times~~ for ancash ~~additional~~at ~~one~~a ~~month~~redemption ~~each~~price ~~time,~~of ~~from~~approximately ~~April~~$11.00 ~~12,~~per ~~2023~~share, ~~the~~for ~~initial~~an ~~Deadline~~aggregate ~~Date,~~redemption toamount upof toapproximately ~~April~~$19.99 ~~12, 2024~~million. ~~In connection with the second Extension~~Consequently, the ~~board~~Contribution ~~delivered~~was ~~the sponsor a written request to draw down~~ $~~160~~50,000 ~~under~~per ~~its~~month ~~previously-disclosed~~needed ~~promissory note~~ for ~~the~~us ~~second~~to ~~month~~continue ofto extend the ~~extension.~~Combination OnPeriod ormonthly. ~~before~~Subsequently ~~May~~in 122024, ~~2023,~~we ~~the~~have ~~sponsor~~made ~~deposited~~additional deposits of $~~160~~50,000 ~~into~~extending the ~~Company’s~~Combination ~~Trust~~Period ~~Account~~through inOctober ~~connection~~12, ~~with the second extension~~2024.

On June 9, 2023, the Company announced that its board of directors has elected to extend the date by which the Company has to consummate a business combination from June 12, 2023 for an additional month to July 12, 2023. In connection with the third extension, the board of directors delivered the sponsor a written request to draw down $160,000 under its previously-disclosed promissory note for the third extension. On or before June 12, 2023, the sponsor deposited $160,000 into the Company’s Trust Account in connection with the third extension.

On July 11, 2023, the Company announced that its board of directors has elected to extend the date by which the Company has to consummate a business combination from July 12, 2023 for an additional month to August 12, 2023. In connection with the fourth extension, the board of directors delivered the sponsor a written request to draw down $160,000 under its previously-disclosed promissory note for the fourth extension. On or before July 12, 2023, the sponsor deposited $160,000 into the Company’s Trust Account in connection with the fourth extension.

On August 9, 2023, the Company announced that its board of directors has elected to extend the date by which the Company has to consummate a business combination from August 12, 2023 for an additional month to September 12, 2023. In connection with the fifth extension, the board of directors delivered the sponsor a written request to draw down $160,000 under its previously-disclosed promissory note for the fifth extension. On or before August 12, 2023, the sponsor deposited $160,000 into the Company’s Trust Account in connection with the fifth extension.

On September 7, 2023, the Company announced that its board of directors has elected to extend the date by which the Company has to consummate a business combination from September 12, 2023 for an additional month to October 12, 2023. In connection with the sixth extension, the board of directors delivered the sponsor a written request to draw down $160,000 under its previously-disclosed promissory note for the sixth extension. On or before September 12, 2023, the sponsor will deposit $160,000 into the Company’s Trust Account in connection with the sixth extension.

On October 12, 2023, we announced that the board of directors has elected to extend the Combination Period for an additional month, from October 12, 2023 to November 12, 2023. In connection with the seventh extension of the extended date, the board of directors delivered the sponsor a written request to draw down $160,000 under the extension promissory note. On October 13, 2023, the sponsor deposited $160,000 into the Trust Account in connection with this seventh extension.

On November 13, 2023, we announced that the board of directors has elected to extend the Combination Period for an additional month, from November 12, 2023 to December 12, 2023. In connection with the eighth extension of the extended date, the board of directors delivered the sponsor a written request to draw down $160,000 under the extension promissory note. On November 13, 2023, the sponsor deposited $160,000 into the Trust Account in connection with this eighth extension.

On December 11, 2023, the Second Extension Amendment Proposal to give the board of directors the right to extend the date by which we must consummate a business combination from December 12, 2023 on a monthly basis up to ten (10) times until October 12,

Table of Contents

2024 (or such earlier date as determined by the board of directors) (the “Second Extension Amendment”) was approved. We filed the Second Extension Amendment with the Cayman Islands Registrar of Companies on December 12, 2023.

On January 19, 2024, we announced that its board of directors had elected to extend the Deadline Date from January 12, 2024 for an additional month to February 12, 2024. The Company’s Amended and Restated Memorandum and Articles of Association provides the Company with the right to extend the Deadline Date eighteen times for an additional one month each time, from April 12, 2023, the initial Deadline Date, to up to October 12, 2024. The board of directors furthermore confirmed their intention and policy to continue to extend the Deadline Date on a monthly basis, but will not announce every month. In the event that the board of directors elects not to extend, they will announce this change in policy.

In connection with the vote to approve the Second Extension Amendment Proposal, the holders of 1,817,650 public shares properly exercised their right to redeem such shares for cash at a redemption price of approximately $11.00 per share, for an aggregate redemption amount of approximately $19.99 million. Consequently, the Contribution will be $50,000 per month needed for us to continue to extend the Combination Period monthly. Subsequently in 2024, we have made additional deposits of $50,000 extending the Combination Period through October 12, 2024.

On October 9, 2024, the Company held the October 2024 Extraordinary Meeting. At the October 2024 Extraordinary Meeting, the Third Extension Amendment Proposal was approved.

In connection with the approval of the Third Extension Amendment Proposal, the sponsor’s Contribution to the Company was the lesser of (x) $50,000 or (y) $ 0.03 for each Class A ordinary share included as part of the units sold in the Initial Public Offering, the public shares, that remains outstanding and was not redeemed for each calendar month (commencing on October 12, 2024 and on the 12th day of each subsequent month) until October 12, 2025, or portion thereof, that is needed to complete a business combination.

In connection with the vote to approve the Third Extension Amendment Proposal, the holders of 1,235,698 public shares properly exercised their right to redeem such shares for cash at a redemption price of approximately $11.58 per share, for an aggregate redemption amount of approximately $14.30 million. Consequently, the Contribution ~~will~~was be $48,311 per month needed for the Company to complete a business combination. The Contribution was deposited into the Company’s U.S.-based Trust Account on October 12, 2024.

OnIn ~~October~~connection ~~12,~~with ~~2024,~~the ~~November~~October ~~13,~~ 2024, ~~December~~Extraordinary 13Meeting, ~~2024,~~the ~~January~~Company ~~17,~~made ~~2025,~~monthly ~~February~~deposits ~~12,~~of ~~2025~~$48,311 ~~March~~into ~~12,~~the ~~2025,~~Trust ~~May~~Account ~~13,~~from ~~2025,~~October ~~June~~2024 ~~13,~~through ~~2025,~~September ~~August 8,~~ 2025, ~~August~~for ~~13,~~an ~~2025~~aggregate ~~and~~amount ~~September~~of 15$579, ~~2025~~735, ~~the~~consisting ~~Company made twelve deposits~~ of $48144,~~311~~934 ~~for~~from ~~November,~~October through December, ~~January,~~2024 ~~February,~~and ~~March~~$434,801 ~~April,~~from ~~May,~~January ~~June,~~through ~~July, August,~~ September ~~and~~2025 ~~October extension contributions, respectively,~~ to extend the Company’s life ~~until~~to October 12, 2025.

On October 10, 2025, the Company held an extraordinary general meeting of its shareholders. At (the ~~meeting,~~“October ~~the~~2025 ~~Fourth~~Extraordinary ~~Extension~~Meeting”). ~~Amendment~~At ~~Proposal to give~~ the ~~Board the right to extend the date by which the Company must consummate a Business Combination from~~ October ~~12,~~ 2025 onExtraordinary ~~a monthly basis up to twelve (12) times until October 12~~Meeting, ~~2026 was approved by depositing into~~ the ~~Company’s~~Fourth ~~trust~~Extension ~~account~~Amendment ~~for~~Proposal ~~each~~was ~~one-month extension the lesser of (a) $40,000 and (b) $0~~approved.~~04 for each then outstanding share after giving effect to any redemptions.~~

In connection with the ~~extraordinary~~approval ~~general~~of ~~meeting,~~the ~~909,330~~Fourth ~~shares~~Extension ~~were~~Amendment ~~tendered~~Proposal, ~~for~~the ~~redemption~~sponsor’s ~~for~~Contribution ~~cash~~to atthe anCompany ~~approximate~~was ~~price~~the lesser of (x) $~~12.34~~ ~~per share~~40,000 or (y) $ 0.04 for aneach ~~aggregate~~Class ofA ~~approximately~~ordinary ~~$11.2~~share ~~million.~~included Onas ~~November~~part 4,of ~~2025,~~the ~~November~~units ~~18,~~sold ~~2025~~in ~~and~~the ~~December~~Initial ~~19,~~Public ~~2025~~Offering, the ~~Company~~public ~~made~~shares, ~~three~~that ~~deposits~~remains ofoutstanding ~~$28,042~~and ~~each~~was ~~into~~not ~~the~~redeemed ~~Company’s~~for ~~trust~~each ~~account~~calendar inmonth ~~connection~~(commencing ~~with~~on ~~November~~October 12, ~~December~~2025 and ~~January~~on ~~2026~~the ~~extension~~12th ~~contributions~~day toof ~~extend~~each ~~the~~subsequent ~~life~~month) until ~~November~~October 12, ~~2025~~2026, ~~December~~or 12portion thereof, ~~2025~~that ~~and~~is ~~January~~needed ~~12,~~to ~~2026,~~complete ~~respectively~~a business combination.

OnIn ~~November~~connection 26with the October 10, 2025 extraordinary general meeting, ~~the~~909,330 ~~Company~~shares ~~was~~were ~~notified~~tendered byfor ~~Continental~~redemption ~~that~~for ~~the~~cash ~~per-share~~at ~~redemption~~an approximate price of $12.35 per share, for ~~the~~an ~~October~~aggregate 10of approximately $11.2 million. On November 4, 2025, ~~redemption~~November of18, ~~public~~2025, ~~shares~~December ~~was~~19, ~~underpaid~~2025, byJanuary ~~approximately~~23, ~~$0.011~~2026, ~~per~~February ~~share~~20, ~~resulting~~2026, inMarch an23, ~~aggregate~~2026, ~~payable~~April of21, $92026,~~998~~ toJune ~~the~~8, ~~investors.~~2026, OnJuly ~~December~~1, 102026 and July 14, ~~2025~~2026, the Company made ~~the~~ten ~~payment~~deposits toof $28,042 each into the ~~investors~~Company’s Trust Account in connection with November 2025, December 2025, January 2026, February 2026, March 2026, April 2026, May 2026, June 2026, July 2026 and August 2026 extension contributions to extend the ~~aggregate~~life ~~amount~~until ofNovember $912,~~998~~ 2025, December 12, 2025, January 12, 2026, February 12, 2026, March 12, 2026, April 12, 2026, May 12, 2026, June 12, 2026, July 12, 2026 and August 12, 2026, respectively.

Contribution and Extension Promissory Note

On April 10, 2023, the Company held the April 2023 Extraordinary Meeting. At the April 2023 Extraordinary Meeting, the Company’s shareholders approved, among other things, a proposal to grant the Company the right to extend the Combination Period to the Extended Date, and to allow the Company, without another shareholder vote, by resolution of the Company’s ~~board~~Board of ~~directors~~Directors, to elect to further extend the Extended Date in one-month increments up to eleven additional times, or a total of up to twelve months total,

3833

Table of Contents

up to April 12, 2024 (the “Extension Proposal”) by amending the Amended and Restated Memorandum and Articles of Association (the “First Extension”).

Under Cayman Islands law, such amendment of the Amended and Restated Memorandum and Articles of Association took effect upon approval of the Extension Proposal. In connection with the vote to approve the Extension Proposal, the holders of 18,336,279 Class A ordinary shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $10.31 per share, for an aggregate redemption amount of approximately $189 million. In connection with each monthly extension in accordance with the First Extension, the sponsor deposited $160,000 into the Trust Account every month from April to November 2023.

Additionally, the sponsor agreed that if the Extension Proposal was approved, it or its designee would deposit into the Trust Account, as a loan, the Contribution on each of the following dates: (i) April 13, 2023; and (ii) one business day following our public announcement disclosing that the ~~board~~Board of ~~directors~~Directors has determined to extend the extended date for an additional month in accordance with the Extension Proposal. Subsequently, the sponsor agreed that if the Extension Proposal was approved, it or its designee would deposit into the Trust Account, as a loan, the Contribution within seven days of the 12th day of each month pursuant to the ~~board~~Board of ~~directors~~Directors determining to extend the extended date for an additional month in accordance with the Second Extension Proposal.

In connection with the Contribution and advances the sponsor may make in the future to us for working capital expenses, on April 13, 2023, the Company issued the original extension promissory note, a convertible promissory note to the sponsor with a principal amount up to $1 million (the “Original Extension Promissory Note”). On September 8, 2023, we issued the amended and restated extension promissory note in the principal amount of up to $2.5 million to the sponsor (the “Amended and Restated Extension Promissory Note”), to amend and restate the Original Extension Promissory Note. The Amended and Restated Extension Promissory Note bears no interest and is due and payable upon the earlier to occur of (i) the date on which the Company consummates its initial business combination and (ii) the date of the Company’s liquidation. At the election of the sponsor, up to $1,500,000 of the unpaid principal balance under the Amended and Restated Extension Promissory Note may be converted into conversion warrants at the price of $1.00 per warrant. Such conversion warrants will have terms identical to the warrants issued to the sponsor in the private placement.

On December 11, 2023, the Company held the December 2023 Extraordinary Meeting. At the December 2023 Extraordinary Meeting, the Second Extension Amendment Proposal to give the ~~board~~Board of ~~directors~~Directors the right to extend the date by which the Company must consummate a Business Combination from December 12, 2023 on a monthly basis up to ten (10) times until October 12, 2024 (or such earlier date as determined by the Board of Directors) (the “Second Extension Amendment”) was approved. Under the law of the Cayman Islands, upon approval of the Second Extension Amendment Proposal by the affirmative vote of at least two-thirds (2/3) of the shareholders entitled to vote, who attended and voted at the December 2023 Extraordinary Meeting (including those who voted online), the Second Extension Amendment became effective. The Company filed the Second Extension Amendment with the Cayman Islands Registrar of Companies on December 12, 2023. Consequently, the Contribution ~~will~~was be $50,000 per month needed for the Company to complete a Business Combination.

On April 18, 2024, we issued the amended and restated promissory note in the principal amount of up to $3.5 million to the sponsor (the “Second Amended and Restated Promissory Note”), to amend and restate the Amended and Restated Extension Promissory Note. The Second Amended and Restated Extension Promissory Note bears no interest and is due and payable upon the earlier to occur of (i) the date on which the Company consummates its initial business combination and (ii) the date of the Company’s liquidation. At the election of the sponsor, up to $1,500,000 of the unpaid principal balance under the Second Amended and Restated Extension Promissory Note may be converted into conversion warrants at the price of $1.00 per warrant. Such conversion warrants will have terms identical to the warrants issued to the sponsor in the private placement.

On October 9, 2024, the Company held the October 2024 Extraordinary Meeting. At the October 2024 Extraordinary Meeting, the Third Extension Amendment Proposal to give the ~~board~~Board of ~~directors~~Directors the right to extend the date by which the Company must consummate a Business Combination from October 12, 2024 on a monthly basis up to twelve(12) times until October 12, 2025 (or such earlier date as determined by the Board of Directors) (the “Third Extension Amendment”) was approved. Under the law of the Cayman Islands, upon approval of the Third Extension Amendment Proposal by the affirmative vote of at least two-thirds (2/3) of the shareholders entitled to vote, who attended and voted at the October 2024 Extraordinary Meeting (including those who voted online), the Third Extension Amendment became effective. Consequently, the Contribution ~~will~~was be $48,311 per month needed for the Company to complete a Business Combination.

3934

Table of Contents

In connection with the Contribution and advances the sponsor may make in the future to us for working capital expenses, on September 20, 2024, the Company issued the third amended and restated extension promissory note in the principal amount of up to $4.5 million to the sponsor (the “Third Amended and Restated Extension Promissory Note”), to amend and restate the Second Amended and Restated Promissory Note. The Third Amended and Restated Extension Promissory Note bears no interest and is due and payable upon the earlier to occur of (i) the date on which the Company consummates its initial business combination and (ii) the date of the liquidation of the Company. At the election of the sponsor, up to a maximum amount of $1,500,000 of the unpaid principal balance under the Notes may be converted into conversion warrants at the price of $1.00 per warrant. Such conversion warrants will have terms identical to the warrants issued to the sponsor in a private placement that closed simultaneously with the Company’s Initial Public Offering.

On October 12, 2024, November 13, 2024, December 13, 2024, January 17, 2025, February 12, 2025, March 12, 2025, May 13, 2025, June 13, 2025, August 8, 2025, August 13, 2025 and September 15, 2025, the Company made twelve deposits of $48,311 for November, December, January, February, March, April, May, June, July, August, September and October extension contributions, respectively, to extend the life until October 12, 2025. On November 4, 2025, November 18, 2025, ~~and~~ December 19, 2025, January 23, 2026, February 20, 2026 and March 23, 2026, April 21, 2026, June 8, 2026, July 1, 2026 and July 14, 2026, the Company made ~~three~~ten deposits of $28,042 each into the Company’s ~~trust~~Trust ~~account~~Account in connection with November 2025, December ~~and~~2025, January 2026, February 2026, March 2026, April 2026, May 12, 2026, June 12, 2026, July 12, 2026 and August 12, 2026 extension contributions to extend the life until November 12, 2025, December 12, 2025, January 12, 2026, February 12, 2026, March 12, 2026 and ~~January~~April 12, 2026, May 12, 2026, June 12, 2026, July 12, 2026 and August 12, 2026, respectively.

As of ~~September~~March 3031, 2026 and December 31, 2025, the outstanding principal under the Third Amended and Restated Extension Promissory Note was $3,955,175.

Founder Conversion

On May 9, 2023, pursuant to the terms of the Amended and Restated Memorandum and Articles of Association and the approval of the Founder Share Amendment Proposal, the sponsor, the holder of an aggregate of 4,002,121 of the Class B ordinary shares, elected to convert each outstanding Class B ordinary share held by it on a one-for-one basis into Class A ordinary shares, with immediate effect in the founder conversion. Following this founder conversion and the redemptions, we had an aggregate of 8,665,842 Class A ordinary shares and 1,747,879 Class B ordinary shares issued and outstanding.

Recent Developments

Nasdaq Notice

On October 9, 2023, the Company received a letter (the “Total Shareholders Notice”) from the Listing Qualifications Department of Nasdaq notifying the Company that it was not in compliance with Nasdaq Listing Rule 5450(a)(2), which required the Company to maintain at least 400 total ~~holders~~shareholders for continued listing on the Nasdaq Global Market. The Total Shareholders Notice stated that the Company had until November 24, 2023 to provide Nasdaq with a plan to regain compliance. On November 24, 2023, the Company provided its plan to Nasdaq for meeting the requirements under Nasdaq Listing Rule 5450(a)(2), and evaluated available options to regain compliance.

On October 12, 2023, the Company filed a Current Report on Form 8-K with the SEC to disclose its receipt of the Total Shareholders Notice in accordance with Nasdaq Listing Rule 5810(b).

On April 30, 2024, the Company received a letter from Nasdaq indicating that the Company did not regain compliance with the Nasdaq Listing Rule 5450(a)(2). Pursuant to the letter, unless the Company requested a hearing before the Nasdaq Hearings Panel by May 7, 2024, the Company’s securities would be subject to suspension and delisting from the Nasdaq Global Market at the opening of business on May 9, 2024, and a Form 25-NSE will be filed with the SEC, which will remove the Company’s securities from listing and registration on Nasdaq. The Company timely requested a hearing before the Nasdaq Hearings Panel and the hearing was held on June 18, 2024. On August 5, 2024, the Nasdaq Hearing Panel granted the Company’s request for continued listing on the Nasdaq Global Market and confirmed that the Company was in compliance with Nasdaq Listing Rule 5450(a)(2).35

Table of Contents

On October 7, 2024, the Company received a notice from the staff of the Listing Qualifications Department of Nasdaq stating that as the Company had not completed an initial business combination within 36 months of the effective date of its registration statement in connection with its Initial Public Offering, it was not in compliance with Nasdaq IM 5101-2 and was therefore subject to delisting. The Company had until October 14, 2024 to request a hearing before the Nasdaq Hearings Panel. The Company decided to request a hearing before the Nasdaq Hearings Panel. Trading in the Company’s securities was suspended at the opening of business on October 14, 2024. The Company had the hearing on December 10, 2024.

On December 10, 2024, the Company received a notice from the Nasdaq Listing Qualifications Hearings acknowledging that the Company had withdrawn its appeal of the October 7, 2024 ~~delist~~delisting determination issued by the Nasdaq Listings Qualifications Staff. Accordingly, trading in the Company’s securities was suspended at the open of trading on December 12, 2024. On June 6, 2025, the Company filed a Form 25 Notification of Delisting with the SEC which removed the Company’s securities from on the Nasdaq Stock Market. The Company’s Common Stock, ~~Rights~~Units and Warrants began to be quoted ~~its~~ on the Pink Markets operated on The OTC Market systems (“OTC Market”) under the symbols “~~IXAQU~~IXQUF,” “~~IXAQA~~IXAQF” and “~~IXAQW~~IXQWF.”

Results of Operations

Our entire activity since inception up to ~~September~~March 3031, ~~2025~~2026 related to our formation, the preparation for the Initial Public Offering, and since the closing of the Initial Public Offering, the search for a prospective initial business combination target and we have been working on the initial business combination since it was entered into. We will not be generating any operating revenues until the closing and completion of our initial business combination, at the earliest. We will generate non-operating income in the form of interest income from the amount held in the Trust Account.

For the three months ended ~~September~~March 3031, ~~2025~~2026, we had net ~~loss~~income of approximately $~~771~~1,960,000, which consisted of approximately $1.39 million from change in fair value of derivative warrant liability, ~~which were partially offset by~~ approximately $~~177~~61,~~700~~000 in ~~operating and formation~~ income, ~~$200,000~~from ofcash ~~benefit~~held ~~from~~in ~~credit~~the ~~loss~~Trust Account and approximately $~~157~~35,~~000~~400 in ~~income~~operating ~~from~~and ~~cash~~formation ~~held in the Trust Account~~income.

For the ~~nine~~three months ended ~~September~~March 3031, 2025, we had net ~~loss~~income of approximately $~~1 million~~242,000, which consisted of approximately $~~1.7~~373,000 ~~million~~ from change in fair value of derivative warrant liability and approximately $~~178~~150,000 in ~~operating~~income ~~and~~from ~~formation~~cash ~~expenses,~~held ~~which~~in ~~were~~the ~~partially~~Trust ~~offset~~Account byand ~~$462,000~~interest in income ~~from~~on ~~cash~~an ~~held~~operating inaccount, ~~the~~which ~~Trust~~were ~~Account~~partially ~~and~~offset by approximately $~~350~~281,000 ofin ~~benefit~~operating ~~from~~and ~~credit~~formation ~~loss~~expenses.

~~For~~As ~~the~~of ~~three~~March ~~months~~31, ~~ended~~2026 ~~September~~and 302025, ~~2024,~~ we ~~had~~recorded ~~net~~a ~~loss~~$3,453,208 ofand ~~approximately~~ $~~281~~1,~~000~~349,167 ~~which~~account ~~consisted~~receivable ofrelated ~~approximately~~to ~~$631,000~~a intarget ~~operating~~delay ~~and~~charge. ~~formation~~Simultaneously, ~~expenses~~a ~~which~~full ~~were~~allowance ~~partially~~for ~~offset~~credit byloss ~~approximately~~of $~~350~~3,~~000~~453,208 inand ~~income~~$1,349,167 ~~from~~were ~~cash~~recognized ~~held~~as inof ~~the~~March ~~Trust~~31, ~~Account~~2026 and 2025, respectively.

For the nine months ended September 30, 2024, we had net loss of approximately $2.3 million, which consisted of approximately $2.2 million in operating and formation expenses and approximately $70 interest expense from bank and a loss of approximately $1.1 million from change in fair value of derivative warrant liability, which were partially offset by approximately $1 million in income from cash held in the Trust Account.36

Table of Contents

Factors That May Adversely Affect Our Results of Operations

Our results of operations and our ability to complete an initial business combination may be adversely affected by various factors that could cause economic uncertainty and volatility in the financial markets, many of which are beyond our control. Our business could be impacted by, among other things, downturns in the financial markets or in economic conditions, increases in oil prices, inflation, increases in interest rates, supply chain disruptions, declines in consumer confidence and spending, and geopolitical instability, such as the military conflict in Ukraine and the Middle East. We cannot at this time fully predict the likelihood of one or more of the above events, their duration or magnitude or the extent to which they may negatively impact our business and our ability to complete an initial business combination.

Table of Contents

Liquidity, Capital Resources and Going Concern

Our liquidity needs to date have been satisfied through the payment of $25,000 from our sponsor to cover for certain offering expenses on behalf of us in exchange for issuance of Founder Shares, a loan under the Initial Public Offering’s promissory note in the amount of $250,000 and advances from our sponsor to cover for certain expenses on our behalf, and net proceeds from the consummation of the Initial Public Offering and the private placement held outside of the Trust Account. We fully repaid the Initial Public Offering’s promissory note balance on October 12, 2021. We also paid for certain expenses on behalf of a related party. As of December 31, 2021, we had approximately $3,500 in amount due from related party outstanding, which was fully paid in April 2022. Subsequently, we borrowed an additional amount of approximately $2,800 and fully settled the balance in July 2022.

As of ~~September~~March 3031, ~~2025~~2026, we had approximately $86373,000 in cash held outside of the Trust Account and a working capital deficit of approximately $6.7 million.

For the ~~nine~~three months ended ~~September~~March 3031, ~~2025~~2026, net cash provided by operating activities was approximately $~~419~~279,000. Net ~~loss~~income of approximately $1,960,000 ~~million~~ was affected by income from cash held in the Trust Account of approximately $~~462~~61,000, change in fair value of warrant liabilities of approximately $1.79 million, ~~benefit from credit loss of $350,000~~ and changes in operating assets and liabilities provided approximately $~~597~~243,000 of cash for operating activities. Cash used in investing activities resulted from monthly extension deposits into the Trust Account of ~~$435,000. Cash provided by financing activities resulted from the proceeds from the Extension Promissory Note of~~ approximately $~~578~~84,000 ~~and repayment of Extension Promissory Note of $480,000~~.

For the ~~nine~~three months ended ~~September~~March 3031, ~~2024~~2025, net cash used in operating activities was approximately $1240,000.2 ~~million.~~ Net ~~loss~~income of approximately $~~2.3~~242,000 ~~million~~ was affected by income from cash held in the Trust Account of approximately $~~1 million~~151,000, change in fair value of warrant liabilities of approximately $~~1.1~~373,000 ~~million~~ and changes in operating assets and liabilities provided approximately $141,000 ~~million~~ of cash for operating activities. Cash used in investing activities resulted from monthly extension deposits into the Trust Account of $~~450~~145,000. Cash provided by financing activities resulted from the proceeds from the Extension Promissory Note of ~~approximately~~ $1386,000.7 ~~million.~~

As of ~~September~~March 3031, ~~2025~~2026, we had cash held in the Trust Account of approximately $~~19.~~8.9 million. We intend to use substantially all of the funds held in the Trust Account, including any amounts representing interest earned on the Trust Account (less taxes payable, if applicable, and deferred underwriting commissions) to complete our initial business combination. To the extent that our equity or debt is used, in whole or in part, as consideration to complete our initial business combination, the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.

We have incurred and expect to continue to incur significant costs in pursuit of our acquisition plans. In connection with our assessment of going concern considerations in accordance with ASC 205-40, we have until October 12, 2026, if all extensions of the extended date are exercised, to consummate a business combination. It is uncertain that we will be able to consummate a business combination by this time, and if a business combination is not consummated by this date, then there will be a mandatory liquidation and subsequent dissolution of our Company.

Our management has determined that the liquidity condition and mandatory liquidation, should a business combination not occur, and potential subsequent dissolution raises substantial doubt about our ability to continue as a going concern for a period of time within one year after the date that the unaudited condensed consolidated financial statements included in this Report ~~under “Item 1~~. ~~Financial Statements” are issued.~~

We plan to address this uncertainty through the initial business combination. There is no assurance that our plans to consummate the initial business combination will be successful or successful within the Combination Period. The unaudited condensed consolidated financial statements and notes thereto included in this Report ~~under “Item 1. Financial Statements”~~ do not include any adjustments that might result from the outcome of this uncertainty.

4237

Table of Contents

Contractual Obligations

Registration Rights Agreement

Underwriters Agreement

In connection with the Initial Public Offering, the underwriters, CF& CO and Odeon, were granted a 45-day option from the date of the prospectus to purchase up to 3,000,000 additional Units to cover over-allotments. On October 12, 2021, the underwriters fully exercised the over-allotment option to purchase an additional 3,000,000 Units at an offering price of $10.00 per Unit, generating additional gross proceeds of $30,000,000 to us.

The underwriters were paid a cash underwriting discount of $0.20 per Unit (excluding over-allotment Units) in the Initial Public Offering, or $4,000,000 in the aggregate upon the closing of the Initial Public Offering. In addition, $0.50 per Unit (excluding over-allotment Units), and $0.70 per over-allotment Unit (totaling $12,100,000 in aggregate) is payable to the underwriters for deferred underwriting commission. The deferred fee is payable to the underwriters from the amounts held in the Trust Account solely in the event that we complete a business combination, subject to the terms of the Underwriting Agreement.

On April 12, 2023, we entered into a Fee Reduction Agreement, which amends the Underwriting Agreement. According to the Underwriting Agreement, we previously agreed to pay to the underwriters of the Initial Public Offering an aggregate of $12,100,000 as deferred underwriting commissions, a portion of which fee is payable to each underwriter in proportion to their respective commitments pursuant to the Underwriting Agreement, upon the consummation of a business combination. Pursuant to the Fee Reduction Agreement, the underwriters have agreed to forfeit sixty-six and 94/100 percent (66.94%) of the aggregate deferred underwriting commissions of $12,100,000 for a total reduction of $8,100,000. However, if we enter into a business combination with a target at a pre-money valuation above $100 million, the forfeiture percentage for underwriters will be reduced to no less than fifty percent (50%) to each, an approximate reduction of $6,050,000. On April 4, 2024, we entered into an Amended & Restated Fee Reduction Agreement, which amends the Underwriting Agreement with ~~Cantor Fitzgerald & Co. (“~~CF&CO”). Pursuant to the Amended and Restated Fee Reduction Agreement with CF&CO, in the event that we consummates the Business Combination, CF&CO agrees that it will forfeit $6,475,000 of the aggregate original deferred fee that would otherwise be payable by us to CF&CO, resulting in a remainder of $1,995,000. On April 4, 2024, we entered into an another Amended & Restated Fee Reduction Agreement, which amends the Underwriting Agreement with Odeon ~~Capital Group LLC (“Odeon”)~~. Pursuant to the Amended and Restated Fee Reduction Agreement with Odeon, in the event that we consummates the Business Combination with AERKOMM, Odeon agrees that it will forfeit $2,775,000 of the aggregate original deferred fee that would otherwise be payable by us to Odeon, resulting in a remainder of $855,000. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that we complete a business combination, subject to the terms of the underwriting agreement.

Administrative Support Agreement

On October 6, 2021, we entered into an agreement with the IX Acquisition Services LLC, to pay up to $10,000 per month for office space, secretarial and administrative services. Upon completion of a Business Combination or the liquidation, we will cease paying these monthly fees; however, the Sponsor waived these fees for ~~the~~ three months ended ~~September~~March 3031, ~~2025~~2026 and ~~2024~~2025.

Off-Balance Sheet Arrangements

As of ~~September~~March 3031, ~~2025~~2026, we did not have any off-balance sheet arrangements.

4338

Table of Contents

Critical Accounting Estimates

The preparation of the unaudited condensed consolidated financial statements and notes thereto included elsewhere in this Report ~~under “Item 1. Financial Statements” and related disclosures~~ in conformity with GAAP requires ~~our~~Management ~~management~~ to make estimates and assumptions that affect the reported amounts of assets and liabilities, income and expenses, and the disclosure of contingent assets and liabilities, in our unaudited condensed consolidated financial statements. These accounting estimates require the use of assumptions about matters, some of which are highly uncertain at the ~~date~~time of estimation. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis for making judgments, and we evaluate these estimates on an ongoing basis. To the extent actual experience differs from the assumptions used, our unaudited condensed consolidated financial statements, and ~~income~~notes ~~and~~thereto ~~expenses~~included ~~during~~elsewhere ~~the~~in ~~periods~~this ~~reported~~Report could be materially affected. ~~Actual~~We ~~results~~believe ~~could~~that ~~materially~~the ~~differ~~following ~~from~~accounting ~~those~~policies ~~estimates~~involve a higher degree of judgment and complexity. WeAs of March 31, 2026, we have identified the following critical accounting ~~policies:~~estimates related to the Private Placement Warrants and Convertible Promissory Note.

~~Class A Ordinary Shares Subject to Possible Redemption~~Warrants

~~All~~We ofaccount for the ~~23,000,000~~warrants ~~Class~~issued Ain ~~ordinary~~connection ~~shares~~with ~~sold as part of~~ the ~~Units~~IPO in ~~the~~accordance ~~Initial~~with ~~Public~~the ~~Offering~~guidance ~~and~~contained ~~subsequent~~in ~~full~~ASC ~~exercise~~815-40. ofSuch ~~the~~guidance ~~underwriters’~~provides ~~over-allotment~~that ~~option~~because ~~contain~~the awarrants ~~redemption~~do ~~feature,~~not ~~which~~meet ~~allows for~~ the ~~redemption~~criteria offor ~~such~~equity ~~public~~treatment ~~shares~~thereunder, ineach ~~connection~~warrant ~~with~~must ~~our~~be ~~liquidation,~~recorded ifas ~~there is~~ a ~~shareholder~~liability. ~~vote~~Accordingly, orwe ~~tender~~classified ~~offer~~each inwarrant ~~connection~~as ~~with~~a ~~the~~liability ~~business~~at ~~combination~~its ~~and~~fair invalue. ~~connection~~This ~~with~~liability ~~certain~~is ~~amendments~~subject to ~~the~~re-measurement ~~Amended~~at ~~and~~each ~~Restated~~balance ~~Memorandum~~sheet ~~and Articles of Association~~date. InWith ~~accordance~~each ~~with~~such ~~SEC and its staff’s guidance on redeemable equity instruments~~re-measurement, ~~which has been codified in ASC 480, redemption provisions not solely within~~ the ~~control~~warrant ofliabilities ~~our~~will ~~Company~~be ~~require~~adjusted ~~ordinary shares subject~~ to ~~redemption~~fair tovalue, bewith ~~classified~~the ~~outside~~change ofin ~~permanent~~fair ~~equity.~~value ~~Therefore,~~recognized ~~all~~in ~~public~~our ~~shares~~statements ~~have been classified outside~~ of ~~permanent equity~~operations.

WeIn ~~recognize~~determining ~~changes~~the infair ~~redemption~~ value ~~immediately~~of ~~as they occur and adjusts~~ the ~~carrying~~Private ~~value~~Placement ofWarrants ~~redeemable~~assumptions ~~ordinary~~related ~~shares~~ to ~~equal~~expected ~~the~~share-price ~~redemption~~volatility, ~~value~~expected atlife ~~the~~and ~~end~~risk-free ofinterest ~~each~~rate ~~reporting~~are ~~period~~utilized. ~~Increases~~The orCompany ~~decreases~~estimates in the ~~carrying~~volatility ~~amount~~ of ~~redeemable~~its ordinary shares ~~are~~based ~~affected~~on byhistorical ~~charges~~volatility ~~against~~that ~~additional~~matches ~~paid~~the inexpected ~~capital~~remaining ~~and~~life ~~accumulated~~of ~~deficit~~the warrants.

~~Derivative~~Convertible ~~Financial~~Promissory ~~Instruments~~Note

WeThe ~~evaluate~~Company ~~our~~determined ~~financial~~that ~~instruments~~the toconversion ~~determine~~feature ifwithin ~~such~~its ~~instruments~~Extension ~~are~~Promissory ~~derivatives~~Note orrequires ~~contain~~bifurcation ~~features that qualify~~ as an embedded ~~derivatives~~derivative inunder ~~accordance with~~ ASC 815. ~~Derivative~~In ~~instruments~~determining ~~are~~the ~~initially recorded at~~ fair value onof the ~~grant~~embedded ~~date~~derivative, ~~and~~assumptions ~~re-valued~~related atto ~~each~~expected ~~reporting~~share-price ~~date~~volatility, ~~with~~expected ~~changes~~term, inrisk-free ~~the~~interest ~~fair~~rate ~~value~~and ~~reported in~~ the ~~statements~~probability of ~~operations~~a ~~included~~Business inCombination ~~this~~are ~~Report under “Item 1~~utilized. ~~Financial~~Based ~~Statements”.~~on ~~The~~these ~~classification of derivative instruments~~assumptions, ~~including~~the ~~whether~~Company ~~such~~determined ~~instruments~~that ~~should~~the befair ~~recorded~~value asof ~~liabilities liquidation is not reasonably expected to require~~ the ~~use~~embedded ofderivative ~~current~~was ~~assets~~$0 oras ~~require the creation~~ of ~~current~~March ~~liabilities~~31, 2026.

We evaluated the Public Warrants and Private Placement Warrants in accordance with ASC 480 and ASC 815 and concluded that a provision in the warrant agreement related to certain tender or exchange offers precludes the Public Warrants and Private Placement Warrants from being accounted for as components of equity. As the Public Warrants and Private Placement Warrants meet the definition of a derivative as contemplated in ASC 815, they were recorded as derivative liabilities on the condensed consolidated balance sheets included in this Report under “Item 1. Financial Statements” and measured at fair value at inception (on the date of the Initial Public Offering) and at each reporting date in accordance with ASC 820, with changes in fair value recognized in the statements of operations included in this Report under “Item 1. Financial Statements” in the period of change. The determination of fair value for the warrant liabilities represents a significant estimate within the condensed consolidated financial statements included in this Report under “Item 1. Financial Statements”.

Convertible Instruments

The Company accounts for its promissory notes that feature conversion options in accordance with ASC 815. ASC 815 requires companies to bifurcate conversion options from their host instruments and account for them as freestanding derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) a promissory note that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

Table of Contents

Recent Accounting Pronouncements

Adopted in fiscal year 2024

To be adopted in future periods

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which requires disclosure of incremental income tax information within the rate reconciliation and expanded disclosures of income taxes paid, among other disclosure requirements. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company’s management does not believe the adoption of ASU 2023-09 will have a material impact on its condensed consolidated financial statements and disclosures.

Management does not believe there are any material recently issued, but not yet effective, accounting standards that, if currently adopted, would have a material effect on our unaudited condensed consolidated financial statements included in this Report ~~under “Item 1~~. ~~Financial Statements”.~~

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this Item.

4539

Table of Contents

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer (together, the “Certifying Officers”), or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

Under the supervision and with the participation of our management, including our Certifying Officers, we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on the foregoing, our Certifying Officers concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Report.

We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Changes in Internal Control over Financial Reporting

There have been no changes to our internal control over financial reporting during the quarterly period ended ~~September~~March 3031, ~~2025~~2026 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

4640

Table of Contents

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

To the knowledge of our Management Team, there is no litigation currently pending or contemplated against us, any of our officers or directors in their capacity as such or against any of our property.

Item 1A. Risk Factors.

As a smaller reporting company under Rule 12b-2 of the Exchange Act, we are not required to include risk factors in this Report. However, as of the date of this Report, other than as set forth below, there have been no material changes with respect to those risk factors previously disclosed in our (i) Registration Statement, (ii) Annual Report on Form 10-K for the fiscal year ended December 31, ~~2024~~2025, as filed with the SEC on April 39, ~~2025~~2026, as supplemented below. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risks could arise that may also affect our business or ability to consummate an initial Business Combination. We may disclose changes to such risk factors or disclose additional risk factors from time to time in our future filings with the SEC.

There is substantial doubt about our ability to continue as a “going concern.”

In connection with our assessment of going concern considerations under applicable accounting standards, Management has determined that our possible need for additional financing to enable us negotiate and complete our initial Business Combination, as well as the deadline by which we may be required to liquidate ~~our~~the ~~trust~~Trust ~~account~~Account, raises substantial doubt about our ability to continue as a going concern through approximately one year from the date the unaudited condensed consolidated financial statements included in this Report under “Item 1. Financial Statements” were issued.

To mitigate the risk that we might be deemed to be an investment company for purposes of the Investment Company Act, on November 13, 2023, we instructed the trustee to liquidate the investments held in the Trust Account and instead to hold the funds in the Trust Account in an interest-bearing demand deposit account at a bank until the earlier of the consummation of our initial Business Combination or our liquidation. As a result, we may receive less interest on the funds held in the Trust Account than the interest we would have received pursuant to our original Trust Account investments, which could reduce the dollar amount our Public Shareholders would receive upon any redemption or our liquidation.

The funds in the Trust Account had, since our Initial Public Offering, been held in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds investing solely in U.S. government treasury obligations and meeting certain conditions under Rule 2a-7 under the Investment Company Act. However on November 13, 2023, to mitigate the risk of us being deemed to be an unregistered investment company (including under the subjective test of Section 3(a)(1)(A) of the Investment Company Act) and thus subject to regulation under the Investment Company Act, we instructed Continental, the trustee with respect to the ~~trust~~Trust ~~account~~Account, to liquidate the U.S. government treasury obligations or money market funds held in the Trust Account and thereafter to hold all funds in the Trust Account in an interest-bearing demand deposit account at a bank until the earlier of the consummation of our initial Business Combination or liquidation. Following such liquidation, we may receive less interest on the funds held in the Trust Account than the interest we would have received pursuant to our original Trust Account investments; however, interest previously earned on the funds held in the Trust Account still may be released to us to pay our taxes, if any, and certain other expenses as permitted. Consequently, the transfer of the funds in the Trust Account to an interest-bearing demand deposit account could reduce the dollar amount our Public Shareholders would receive upon any redemption or our liquidation.

In the event that we may be deemed to be an investment company, we may be required to liquidate the Company.

Military or other conflicts in Ukraine, the Middle East or elsewhere may lead to increased volume and price volatility for publicly traded securities, or affect the operations or financial condition of potential target companies, which could make it more difficult for us to consummate an initial Business Combination.

Military or other conflicts in Ukraine, the Middle East or elsewhere may lead to increased volume and price volatility for publicly traded securities, or affect the operations or financial condition of potential target companies, and to other company or industry-specific, national, regional or international economic disruptions and economic uncertainty, any of which could make it more difficult for us to identify a Business Combination target and consummate an initial Business Combination on acceptable commercial terms or at all.

4741

Table of Contents

If the Company is deemed to be an investment company for purposes of the Investment Company Act, the Company may be forced to abandon its efforts to complete the Business Combination and instead be required to liquidate. To mitigate the risk of that result, as of November 13, 2023, the Company has moved its Trust Account from investments in securities to an interest-bearing bank demand deposit account.

There is currently uncertainty concerning the applicability of the Investment Company Act to a SPAC. It is possible that a claim could be made that the Company has been operating as an unregistered investment company, including under the subjective test of Section 3(a)(1)(A) of the Investment Company Act, based on the current views of the SEC. If the Company was deemed to be an investment company for purposes of the Investment Company Act, the Company might be forced to abandon its efforts to complete the Business Combination and instead be required to liquidate. If the Company is required to liquidate, the Company would not be able to complete the Business Combination and investors would not be able to realize the benefits of owning shares in AKOM Inc., including the potential appreciation in the value of the shares and warrants following such a transaction, and the Company’s warrants would expire worthless.

Prior to December 31, 2023, the funds in the Trust Account were held only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds investing solely in U.S. government treasury obligations and meeting certain conditions under Rule 2a-7 under the Investment Company Act. Nevertheless, to mitigate the risk of the Company being deemed to have been operating as an unregistered investment company under the Investment Company Act, as of November 13, 2023, the Company has instructed Continental Stock Transfer & Trust Company, the trustee with respect to the Trust Account, to liquidate the U.S. government securities or money market funds held in the Trust Account and, thereafter, to hold all funds in the Trust Account in an interest-bearing bank demand deposit account until the earlier of the consummation of our business combination or our liquidation.

The SEC has recently issued final rules relating to certain activities of SPACs. Certain of the procedures that we, a potential business combination target, or others may determine to undertake in connection with such proposals may increase our costs and the time needed to complete a business combination and may make it more difficult to complete a business combination. The need for compliance with the SPAC Final Rules may cause us to liquidate the Company at an earlier time than we might otherwise choose.

On January 24, 2024, the SEC adopted final rules (the “SPAC Rules”) relating, among other things, to disclosures in SEC filings in connection with business combination transactions between special purpose acquisition companies (“SPACs”) such as us and private operating companies; the financial ~~statement~~statements requirements applicable to transactions involving shell companies; and the use of projections by SPACs in SEC filings in connection with proposed business combination transactions. SPACs will be required to comply with the SPAC Rules beginning July 1, 2024. In connection with the issuance of the SPAC Rules, the SEC also issued guidance (the “SPAC Guidance”) regarding the potential liability of certain participants in business combination transactions and the extent to which SPACs could become subject to regulation under the Investment Company Act of 1940, as amended (the “Investment Company Act”). The need for compliance with the SPAC Rules and the SPAC Guidance may cause us to liquidate the Company at an earlier time than we might otherwise choose. Certain of the procedures that we or others may determine to undertake in connection with the SPAC Rules, the SPAC Guidance, or before July 1, 2024 as a matter of practice in light of the SEC’s previously expressed views, may increase the costs and time of negotiating and completing an initial business combination, including the transaction with respect to the Merger Agreement, and may constrain the circumstances under which we could complete an initial business combination. The need for compliance with the SPAC Rules and the SPAC Guidance may cause us to liquidate the Company at an earlier time than we might otherwise choose. Were we to liquidate, our warrants would expire worthless, and our securityholders would lose the investment opportunity associated with an investment in the combined company, including any potential price appreciation of our securities.

4842

Table of Contents

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Unregistered Sales of Equity Securities

None.

Use of Proceeds

For a description of the use of proceeds generated in our Initial Public Offering and Private Placement, see Part II, Item 5 of the 2021 Annual Report. There has been no material change in the planned use of proceeds from the Initial Public Offering and Private Placement as described in the Registration Statement. The specific investments in our Trust Account may change from time to time.

On November 13, 2023, we instructed Continental to liquidate the investments held in the Trust Account and instead to hold the funds in the Trust Account in an interest-bearing demand deposit account at a bank, with Continental continuing to act as trustee, As a result, following the liquidation of investments in the Trust Account, the remaining proceeds from the Initial Public Offering and Private Placement are no longer invested in U.S. government securities or money market funds.

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

4943

Table of Contents

Item 6. Exhibits.

The following exhibits are filed as part of, or incorporated by reference into, this Report.3

No.		Description of Exhibit
10.1		Amended and Restated Promissory Note, dated September 8, 2023, issued to IX Acquisition Sponsor LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on September 12, 2023).
31.1		Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
31.2		Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
32.1		Certification of the Principal Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
32.2		Certification of the Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
101.INS		Inline XBRL Instance Document.*
101.SCH		Inline XBRL Taxonomy Extension Schema Document.*
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.*
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.*
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.*
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.*
104		Cover Page Interactive Data File (Embedded as Inline XBRL document and contained in Exhibit 101).*

* Filed herewith.

** Furnished herewith.

5044

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: December 23, 2025	IX Acquisition Corp.
Dated: July 16, 2026	IX Acquisition Corp.
	By:	/s/ Noah Aptekar
	Name:	Noah Aptekar
	Title:	Chief Executive Officer, Chief Financial Officer and Chief Operating Officer
		(Principal Executive Officer and Principal Financial Officer)

5145

Filing Compare · IX Acquisition Corp.